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1. SUMMARY 
Osteoarthritis (OA) is one of the equine diseases with the greatest economic impact in the 
industry. Responsible for 60% of lameness, OA is considered one of the main causes of 
premature abandonment of sports life in horses. 
Despite its high economic impact on both direct and indirect costs, few new treatments have 
been developed for the treatment of equine OA in recent decades. 
Non-steroidal anti-inflammatory and / or corticosteroid accompanied by nutritional 
supplements are the most commonly used conventional treatments in the equine clinic, 
however, conventional treatments are associated with positive doping in sport horses and can 
have important medium-long term side effects.  
The objective of this work was to demonstrate the safety and efficacy of a new product of 
advanced therapies based on Equine Umbilical Cord Mesenchymal Stem Cells (EUC-MSC) as 
treatment of equine OA. 
To achieve the objective a superiority, controlled, blind, randomized and multicentre clinical 
study, has been designed  and conduct following the European and Good Clinical Practices 
guidelines (VICH 9- GCP). 
In addition to the main objective, the present work has deep in the knowledge of the EUC-
MSC efficacy, for that different epidemiological covariates such as age, chronicity of 
symptoms, the type of joint affected or the degree of sporting level of the animal has been 
analysed in order to discover if there were specific equine populations where the EUC-MSC 
are not effective. 
Likewise, a comparative study on the efficacy-safety-price balance of the treatment with EUC-
MSC has been made in comparison with conventional treatments in order to discover if EUC-
MSC can be considered a real therapeutic alternative. 
The present study has demonstrated a robust efficacy of EUC-MSC in the reduction of 
lameness in horses affected by OA. 72% of the horses treated with EUC-MSC showed a 
reduction in the level of lameness, presenting non-lameness or an inconsistent lameness, 
allowing the horses to return to the same level of sport activity than after the injury. 
The study of epidemiological covariates found that the efficacy of EUC-MSC is consistent, not 
being affected by epidemiological factors such as age, chronicity of symptoms or the degree 
of sports activity.  
Finally, it has been established that in a comparative efficacy-safety-price chart, EUC-MSC 
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RESUMEN 
La Osteoartrosis (OA) equina es una de las enfermedades equinas de mayor impacto económico 
en la industria. Responsable del 60% de las cojeras equinas, la OA es considerada una de las 
principales causas de abandono prematuro de la vida deportiva en équidos. 
A pesar de su alto impacto económico tanto en costes directos como indirectos, pocos 
tratamientos nuevos han sido autorizados para el tratamiento de la OA equina en las últimas 
décadas. 
Los tratamientos farmacológicos especialmente antiinflamatorios no esteroides y/o corticoides 
acompañados de complementos nutricionales son los tratamientos convencionales más utilizados 
en la clínica equina, sin embargo, los tratamientos convencionales están asociados a doping en 
caballos de competición y pueden suponer importantes efectos secundarios a medio-largo plazo. 
El objetivo de este trabajo es demostrar la seguridad y eficacia de un nuevo producto de terapias 
avanzadas basado en células madre mesenquimales de cordón umbilical equino (EUC-MSC) en el 
tratamiento de la OA equina. 
Para conseguir el objetivo un estudio clínico de superioridad, controlado, ciego, aleatorizado y 
multicéntrico, ha sido diseñado siguiendo las guías y directrices europeas de Buenas Prácticas 
Clínicas (VICH 9 guidelines). 
Adicionalmente al objetivo principal, el presente trabajo ha tratado de estudiar ampliamente la 
eficacia de las EUC-MSC teniendo en cuenta diferentes covariables epidemiológicas como la edad, 
la cronicidad de los síntomas, el tipo de articulación afectada o el grado de nivel deportivo del 
animal; con el fin de descubrir si había poblaciones especificas donde las EUC-MSC no son tan 
efectivas. 
Así mismo, se ha hecho un estudio comparativo sobre el balance eficacia-seguridad-precio del 
tratamiento con EUC-MSC en comparación con los tratamientos convencionales con el fin de 
descubrir si efectivamente las EUC-MSC pueden suponer una alternativa terapéutica. 
El presente estudio ha demostrado una sólida eficacia de las EUC-MSC en la reducción de la cojera 
en caballos afectados por OA. El 72% de los caballos tratados con EUC-MSC presentaron una 
reducción del nivel de cojera, quedando sin cojera o con una cojera inconsistente, permitiendo 
que los caballos volviesen a su mismo nivel de actividad deportiva posterior a la lesión.  
El estudio de covariables epidemiológicas descubrió que la eficacia de las EUC-MSC es consistente 
no viéndose afectadas por factores epidemiológicos como la edad, la cronicidad de los síntomas o 
el grado de actividad deportiva.  
Por último, se ha establecido que en una comparativa eficacia-seguridad-precio las EUC-MSC 
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2. ABBREVIATIONS 
AAEP: American Association of Equine Practitioners 
AEMPS: Agencia Española de Productos Sanitarios  
ADAMTS: a disintegrin and metalloproteinase with thrombospondin motifs 
AT: Adipose Tissue  
BM: Bone Marrow  
CD: Cluster of Differentiation 
CCL: Chemokine (C-C motif) Ligand 
COs: Corticosteroids 
COXs: cyclo-oxygenases  
CP: Control product  
CSP: Chondroitin sulfate  
CTX-II: C-telopeptide of type II collagen  
EMA: European Medicine Agency 
EUC-MSCs: Equine Umbilical Cord derived Mesenchymal stem cells  
FAO: Food and Agriculture Organization 
FEI: Fédération Equestre Internaciale  
GAG: Glicosaminoglycans 
HA: Hyaluronic Acid 
HLA: Human Leukocyte Antigen 
IA: intra-articular  
IDO: indoleamine- 2,3-dioxygenase  
INF: Interferon 
IIAB: Intra-articular Anesthetic Block 
IL: Interleukin 
ISCT: The International Society for Cellular Therapy  
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IVP: Investigational Veterinary Product  
M: Macrophages  
MA: Marketing Authorization 
MHC: Mayor Histocompatibility Complex 
MLR: Mixed Lymphocytes Reaction 
MMP: Metalloproteinases 
MoA: Mechanims of Action  
MSCs: Mesenchymal stem cells  
NO: Nitric Oxygen 
NSAIDs : Non-steroidal anti-inflammatory drugs  
OA: Osteoarthritis 
PBMCs : Peripheral blood mononuclear cells  
PGE2: Prostaglandin E2  
PGs: Prostaglandins  
PHA: Phytohemagglutinin  
PP: Population by protocol  
PPT: Population to be treated  
PSGAG: Polysulphated glycosaminoglycans  
SF: Synovial Fluid 
Tc: Citotoxic T-cells  
TGF: Transforming growth factor 
Th: T-helper cells 
TIMP: Tissue inhibitor of Metalloproteinases    
TNF: Tumor Necrosis Factor  
Treg: T-regulatory cell  
WJ: Wharton’s jelly  
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3. INTRODUCTION 
The equine skeletal system is comprised of more than 200 bones that interconnect with the 
assistance of connective tissues such as tendons, ligaments, and cartilage. Where two or more 
bones meet it is considered a joint. Joint, is defined in anatomy as a structure that separates 
two or more adjacent elements of the skeletal system.  
There are three basic types of joints in horses: fibrous, cartilaginous and synovial. 
a. Fibrous Joints:  
In fibrous joints, bones are connected by dense connective tissue fibres (collagen), which pass 
from one part to the other. Fibrous joints are less common in the equine body; these joints do 
not allow for movement.  
An example of fibrous joints would be those between the bones making up a horse’s skull and 
the articulations between the bodies of the vertebrae that make up the axial skeleton. 
Fibrous joints are the least likely to be afflicted with disease because they are more or less 
immobile. 
 
b. Cartilaginous Joints: 
In cartilaginous joints, the interface consists of hyaline or fibrous cartilage. Examples of these 
joints are the intervertebral disk and the symphysis of the pubic bones in both human and 
horses.   
Cartilaginous joints don't have a high propensity for disease because they have limited 
movement. These are the joints of the pelvis and vertebrae as well as growth plates, which 
extend a bone's length during the horse's growing years. 
c. Synovial Joints: 
The basic structure of all synovial joints is the same, regardless of the type or location. All 
synovial joints have (Figure 1): 
- Two or more bones (ending with a plate of subchondral bone) covered with a thin 
layer of articular cartilage. The articular cartilage is smooth and resilient and enables 
frictionless movement of the joint. 
- A synovial fluid-filled cavity between the articulating bones, which provides lubrication 
within the joint itself.  
- A synovial membrane.  
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A synovial joint is more than simply the union of two or more bones; the joint could be 
considered as an organ.  
The highly specialized tissues of the synovial joint come together to perform two main 
functions: Enable movement and transfer load from one bone to another.  
In a normally functioning joint, both of these tasks are achieved in an efficient and pain-free 
manner. The secret of how this frictionless, painless movement occurs relies on all the joint 
elements functioning in concert, but requires the involvement of healthy articular cartilage 
lining bones.  
Articular cartilage is an extremely specialised connective tissue capable of withstanding very 
high loads during physical activity. It is composed largely of water (70- 80%), type II collagen 
and proteoglycan molecules such as aggrecan and chondrocytes (cartilage cells). On a normal 
INTRODUCTION 
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microscopic section, the articular cartilage appears as a glasslike structure containing cells. 
The glasslike material outside the cells is called matrix. The matrix is made up of a framework 
of collagen, and within the framework molecules called proteoglycans are contained, as well 
as water (Figure 2). 
 
Figure 2: Diagram of adult articular cartilage showing four layers and arrangement of chondrocytes and collagenous fibres 
(Wayne McIlwraith; Colorado State University) 
 
The chondrocytes are responsible for synthesising, organising, and regulating the extracellular 
matrix of the articular cartilage. The extracellular matrix is the tissue surrounding the 
chondrocytes where water, collagen, and proteoglycans are found. The type II collagen forms 
a fibrillar network within the extracellular matrix, which is responsible for maintaining the 
shape and strength of the tissue. Also found within the extracellular matrix are large, 
negatively-charged macromolecules called proteoglycans. These are a mixture of proteins and 
long chains of sugar that attract large amounts of water, but repel each other. The most 
common proteoglycan in articular cartilage is the aggrecan—a very large proteoglycan that 
plays a pivotal role in the function of articular cartilage.  
During weight bearing, the aggrecan molecules, which are already very tightly packed 
together, become further compressed. During this compression, water molecules (that were 
attracted to the negatively-charged aggrecan molecules) are forced from the extracellular 
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matrix of the cartilage, and all of the negatively charged branches of the aggrecan molecule 
repel each other like similar ends of a magnet. That is, the bones are protected by this layer of 
shock-absorbing articular cartilage, and the load is transmitted from one bone to another. 
Synovial Fluid 
Joints are lubricated by Synovial Fluid (SF), produced by specialised lining cells, called 
synoviocytes. The cells produce hyaluronic acid as well as other constituents of synovial fluid, 
including glycosaminoglycans (GAG). These proteins impart viscosity to the fluid, which is 
subjectively assessed as part of synovial fluid analysis. A small volume of synovial fluid can 
normally be extracted from joints in all species (up to 1-2 ml can be extracted from equine 
joint fluids) and is colourless to light yellow and quite viscous. 
In normal, not pathologic, synovial fluid the following characteristic can be found 
(eClinPath.com): 
 Gross appearance: Colourless to light yellow, transparent.  
 Nucleated cell counts: This is species-dependent, but counts are usually less than 
1,000/uL. 
o Dogs: Counts vary between joints, with higher counts seen in some joints. We 
generally use 3,000/uL as an upper limit of normal in this species. 
o Cats: One study showed average counts of 161 cells/ul, with a range of 2-
1,134/uL in fluids with minimal blood contamination (RBC counts were up 
to 4,535/uL). We generally use <1,000/uL as the upper limit of normal. 
o Horses: In most horses, counts are <500/uL, but counts up to 1,350/uL have 
been reported in healthy horses and we commonly see counts of <1,000/uL.  
o Cattle: Similar to horses. 
 Red blood cell counts: This should be low (<1,000/uL) unless there is blood 
contamination or haemorrhage (uncommon) during the SF extraction. In a freshly 
prepared smear of fluid, erythrophages would support recent haemorrhage into the 
joint.  
 Total protein: This is usually <2.5 g/dL, although fluid from normal horses has a protein 
as low as 1.5 g/dL. 
 Viscosity: A strand of 2 cm should form between two objects. Decreased viscosity is 
seen with degenerative joint disease, trauma, inflammatory joint disease, 
hydroarthrosis, hemarthrosis and haemodilution. 
 Smear assessment: Normal joint fluid is viscous and of low cellularity. Cells are 
comprised of 50-90% mononuclear cells, of which 80% or more are macrophages or 
synovial lining cells with <20% lymphocytes. There are usually <10% neutrophils (non-
degenerate). Most macrophages are not “activated” – due to lack of cytoplasmic 
vacuolation, do not demonstrate phagocytic activity and have eccentric round 
monocytoid nuclei. Some clinical pathologists use the term “large mononuclear 
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cells” and “small mononuclear cells” demonstrating the difficulty of distinguishing 
macrophages from synoviocytes and quiescent (non-activated) synoviocytes or 
macrophages from small lymphocytes. If there are sufficient cells (rarely in a normal 
joint fluid) or mild blood contamination, the cells will line up in streams in the smear 
(called “windrowing”), implying normal or retention of viscosity. 
In synovial fluids from horses with Osteoarthrosis (OA), in general, the changes observed in 
synovial fluid from injured or diseased joints are brought about by alterations in the 
permeability of the synovial membrane and impairment of its normal secretory functions. 
Because of the importance of the synovial membrane in maintaining the proper fluid 
composition, the physiological function of the fluid and membrane are inextricably linked. In 
fact, synovial fluid analyses have been postulated as an early disease indicator in OA (Ma et 
al., 2017; de Grauw et al., 2006). 
Reductions in relative viscosity in the SF can occur by two separate mechanisms; simple 
effusion or synovitis. Synovial effusion often results from direct trauma to the joint and the 
resulting reduction in viscosity arises from the dilution of the synovial fluid by the influx of 
plasma into the joint space. In inflammatory conditions (synovitis), viscosity can be further 
reduced through decreased synthesis of hyaluronic acid as well as incomplete polymerization 
(shorter chain lengths). When both simple effusion and synovitis occur simultaneously the 
viscosity of the synovial fluid may be little more than that of water. Since hyaluronic acid is 
responsible for the viscosity of synovial fluid, its concentration is similarly reduced by synovitis 
and effusion.  
Normally the protein concentration of synovial fluid is considerably less than that of the 
serum. Thus, any injury or condition which causes vascular leakage in the synovial membrane 
will be accompanied by an influx of fluid and protein into the joint space and surrounding 
tissue producing oedema.  
Minor elevations in the leukocyte content occur in many common joint disorders and reflect 
the degree of the inflammatory response. Marked increase in white cells is highly suggestive 
of an infectious aetiology. Although cartilage fragments are not truly a property of synovial 
fluid, their presence in the fluid is indicative of degeneration and erosion of the articular 
surfaces. Cartilage fragments occur in the synovial fluid as a result of mechanical wear of the 
articular surfaces and with damage or disease the rate and extent of articular degeneration 
can dramatically increase. Minor cartilage erosion appears to be a normal consequence of 
aging and articular fragments are common in the synovial fluid of the elderly. Large amounts 
of cartilage debris are, however, indicative of significant lesions or deterioration of the 
articular surfaces. Erosion of the articular cartilage is an important factor in the overall 
pathogenesis of many degenerative joint conditions and may contribute significantly to 
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3.1. Osteoarthritis 
3.1.1. Physiopathogenesis 
One of the most prominent OA researchers agreed on the following definition of OA: 
“Osteoarthritis can be described as the failed repair of damage that has been caused by 
excessive mechanical stress (defined as force/unit area) on joint tissues” (Brandt et al., 2009). 
Osteoarthritis (OA) is a painful, chronic, debilitating joint disease with no known cure in 
horses. It is characterized by heat, pain, swelling, crepitus, and a decreased range of motion in 
affected joints.  
This condition can develop suddenly (e.g., secondary to a traumatic injury to the joint), or it 
can develop slowly over the course of months to years. Trauma to the joint, immobilization of 
the joint, poor conformation, improper shoeing and age are often preliminary factors that 
contribute to the onset of OA in the horse (Schlueter & Orth, 2004). 
In the horse, synovitis is also regarded as an important primary, or at least concomitant, 
event. Irrespective of whether there are only single or multiple primary factors, there is 
general consensus that after this primary event a vicious cycle may ensue that comprises both 
inflammatory and degradative components. Synovial inflammation is an important 
component of OA, contributing to the dysregulation of chondrocyte catabolic and anabolic 
activities (Van Werren & de Grauw, 2010) 
OA is characterized by progressive loss of articular cartilage and the existence of an 
inflammatory environment and the presence of matrix degrading and inflammatory cytokines. 
It usually has a chronic character and affects all joint structures as bursa, synovial fluid, 
cartilage and subchondral bone. 
It is thought to start as result of damage to the joint tissue by physical forces as a single event 
of trauma or by repeated microtrauma due to altered mechanical loading of the joint. 
Synoviocytes and Chondrocytes responds to the physical injury by stopping the production of 
anabolic factors and by releasing more catabolic enzymes such as metalloproteinases (MMPs), 
Interleukin 1 (IL-1) and Tumor Necrosis Factor α (TNF-α) which results in further damage to 
the cartilage (Souza. 2016) 
As shown in the Figure 3, during the development of OA the immune response play an 
important role in the evolution and degeneration of the disease (Haseeb et al., 2013; Lange-
Brokaar et al., 2012; Manferdini et al., 2013; Ma et al., 2017): 
1. On one hand, the Synovial Fluid and Synovial membrane have an important infiltrate 
of immune cells including macrophages (65%), T-cells (22%) and B-cells (5%). 
2. On the other hand, multiple proinflammatory soluble factors such as cytokines ((IL1, 
IL-6, TNF-α), chemokines (CS846, GAG, HA and CTX-II) and metalloproteinases (MMP-
INTRODUCTION 
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9, MMP-13, ADAMTS-5,) are released by different cell types not limited to immune 
cell, but also synoviocytes and chondrocytes. This secretion forms inflamed synovium 
and develops the degradation of the cartilage matrix that results in further progression 
of OA symptoms. Among the cytokines, IL-1β, TNF-α and IL-6 are three main pro-
inflammatory responsible for the shift of cartilage homeostasis towards more 
catabolism and degradation of cartilage. In addition, TNF- α, MMP-3 and MMP-2 have 
been related to be the most important inflammatory reagents related to lameness 
grade progression in horses (Ma et al., 2017). 
 
 
Figure 3: Physiopathogenesis of OA Kapoor et al., 2011 
 
TNF-α is the prime mediator of the acute inflammatory response and promotes the release of 
IL-1. MMPs are enzymes responsible for the physiological remodeling of the cartilage, but 
when they are increased, thanks to the upregulated by IL-1 and TNF, they alter the normal 
regulation of cartilage matrix causing their destruction. 
In response to the chronic and progressive loss of cartilage, subchondral bone responds by 
stimulating the osteosynthesis which causes the formation of new bone and osteophytes 
(bone spurs) in bone articular surface and general articular incongruity, which triggers chronic 
joint changes (Figure 4). 
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Figure 4: Example of Osteophyte in equine tarsal joint 
 
Because of all these mechanisms, joints affected by OA have a chronic inflammatory 
environment, chronic cartilage destruction, loss of joint congruence and clinical sings as pain, 
heat, lameness and loss of sports capabilities. 
 
3.1.2. Economic Impact of OA 
OA is a common disorder in horses with a prevalence as high as 80% in both young and old 
animals (Souza. 2016). OA is considered the most common joint disease in horses, responsible 
of 60% of lameness in horses (Kim et al., 2003). The most common causes of poor 
performance and early retirement of equine athletes are joint pain and loss of mobility due to 
osteoarthritis (Todhunter and Lust, 1992). 
Osteoarthritis is expensive to manage per horse to diagnose, treat, and medicate, in addition 
the value of a horse affected by osteoarthritis also decreases substantially (McIlwraith, 2010).  
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Lameness examination 
75-500€ (depending on extent of examination, blocking, 
etc.) 
Radiologic (per joint) 120-150€ 
Conventional treatments 
(Corticosteroid + hyaluronic 
acid) 
200-300€ 
(approx. 800€/year considering the time of effectiveness 
of the treatment) 
Physical therapy and related 
techniques (aqua treadmill, 
massage, electrical therapies, 
cold therapies, etc.   
 
100€ (session) 
Oral Joint health supplements 
3€/day 
1095€/year 
Table 1: Estimation of direct cost of OA diagnosis and treatment in Europe (based in USA estimations publish by Oke. (2009) 
In addition to direct cost, the indirect costs (lost sports days, decrease in the economic value 
of the horse, expenses associated with the maintenance and care of the injured horse, etc.) of 
OA are very high in equine practices. It has been estimated that the direct costs of OA in 
humans only represents the ~30% of the total impact of the OA, so to the direct cost an 
increase of 250% should be added as indirect costs (Coyte & Chan. 1998). 
However, it has been suggest that while indirect costs are rarely considered in veterinary 
medicine, the estimates of indirect costs associated with equine OA projected from human 
research are likely substantially higher than they are in reality (Oke. 2009) 
Per year, the direct medical costs could amount to approximately 2.500€. If one considers 
indirect expenses, the cost of this horse could be substantially higher—perhaps as high as 
12,000€/year (Oke &Mcllwraith. (2010)). 
Bearing in mind that there are 5.7 million horses in Europe (Food and Agriculture Organization 
(FAO) 2009) and considering that 60% of lameness in horses is caused by OA (Oke & 
Mcllwraith, 2010) and that 46% of active horses are lame (Greve & Dyson, 2014), it can be 
estimated that in Europe there are a total of 1.57 million lame horses due to the OA. 
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Figure 5: Number of horses lame due OA in Europe 
 
With a total cost of € 12,000 per year and per horse and 1.6 million lame horses due to the OA 
in Europe, the total economic impact of the OA in the European equine sector can amount to 
18,000 million Euros per year. 
 
3.1.3. Treatment 
Conventional treatments for OA in horses are mainly focused on relieving this inflammation 
and controlling pain (Barrachina et al., 2017). The classic treatment of OA in horses has been 
basically symptomatic by inhibiting the synthesis of eicosanoids through the use of non-
steroidal anti-inflammatory drugs (NSAIDs) or intra-articular corticosteroids (COs). Currently, 
the use of hyaluronic acid (HA), polysulphated glycosaminoglycans (PSGAG) and 
pentosanpolysulfate have great acceptance in equine clinical practice (Goodrich and Nixon 
2006). These substances have no anti-inflammatory effect mediated by blocking the 
eicosanoid cascade. However, they promote the metabolism of articular cartilage and reduce 
synovial effusion. Generally, these substances are not used as a single treatment. Many 
clinicians combine them with intra-articular COs. The drugs used in OA can be classified into 
three general groups: 
a) Nonsteroidal anti-inflammatory drugs (NSAIDs) are used in equine OA because they 
reduce pain and synovial effusion. Its action is symptomatic, although some molecules 
can be protective of the articular cartilage. NSAIDs belong to different groups that 
have no chemical relationship with each other, but have a common mechanism of 
5.7M 
Total of horses in EU 
2.6M 
Total of lame horses 
1.6M 
Total of lame horses 
affected by OA 
•(Food and Agriculture 
Organization,2009)  
•Greve & Dyson, 2014 
•Oke & Mcllwraith, 2010 
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action, the inhibition of the synthesis of inflammatory prostaglandins (PGs) by blocking 
the enzymes cyclo-oxygenase (COXs). The most commonly used NSAID in equine 
practices is phenilbutazone (Mcllwraith,2004). Due to the pharmacokinetic 
characteristics of the NSAIDs, they must be administered daily to maintain their 
therapeutic effect (Foreman & Roummler, 2011) so the treatment of equine OA with 
NSAIDs requires daily treatment of the animal, which is a disadvantage for the owner. 
Likewise, the use of long-term NSAIDs is associated with adverse effects on the equine 
digestive system, especially gastric ulcers, and / or kidney problems. It has been 
suggested that long-term use of nonsteroidal anti-inflammatory drugs might enhance 
the pathologic process of cartilage degeneration (Van Weeren & de Grauw, 2010). We 
should not forget that the use of NSAIDs in horses is considered doping, so no horse 
for sporting purposes could be treated continuously with NSAIDs and continue with 
their sporting career (Knych, 2017).  
b) Corticosteroids (COs) are the most used currently in equine practices for OA 
treatment. COs act on the metabolism of arachidonic acid by relieving the 
inflammation that causes swelling, heat and pain (van Weeren and de Grauw 2010, 
McIIwraith, 2010). The anti-inflammatory effect occurs quickly and effectively, with a 
consequent decrease in lameness. However, the used of COs is associated with 
important disadvantages because of their adverse results in the metabolism of 
chondrocytes by inhibiting the synthesis of proteoglycans and changing the structure 
of collagen networks (Souza et al., 2016). Moreover, clinical and experimental results 
are also contradictory, although studies have indicated that these drugs, when 
administered at low doses are effective and safe, COs should be used carefully with 
respect to dosage and the frequency and extent of application (Goodrich and Nixon 
2006). Because they are immunosuppressive drugs, inhibit proteoglycan synthesis, 
alter collagen structure, and suppress the biosynthetic activities of many cell types, 
including chondrocytes (Souza et al., 2016) COs could negatively affect the cartilage 
homeostasis. In fact, studies have shown that negative impact of COs on the matrix 
occur if high doses are used, when the treatment is repeated continuously, or when 
the drugs are used in healthy joints (Souza et al., 2016). On the other hand, Frean et 
al., (2002) reported adverse responses even when low doses were administered. In 
addition to the local adverse events described before, the use of COs has been also 
associated to systemic adverse event as laminitis, endotoxemia and gastrointestinal 
tract disorders (Johnson PJ, 2012). In addition, COs are also considered doping and in 
the case that COs are used in sport horses a withdrawal period of about 15 days 
(Federation Equestre Internationale  guidelines) is needed. 
c) Modifying drugs for osteoarthritis such as Hyaluronic acid (HA) which is an 
unsulphated glycosaminoglycan. It is produced by synoviocytes and is responsible for 
promoting joint lubrication. The HA can modify the course of the OA for two reasons: 
1) Production of modulating effects of the biological response mediated by specific 
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receptors of the cellular membrane of leukocytes and articular cells. 2) Mechanical 
interference of the interaction between catabolic proteins and their cellular receptors. 
HA produces inhibition of white cell migration, traps free radicals and possesses 
chondroprotective actions, since it promotes the synthesis of proteoglycans. 
Polysulphated glycosaminoglycans (PSGAGs) are sulphate-rich polysaccharides 
produced by chondrocytes and make up the extracellular matrix of articular cartilage. 
PSGAGs can be used intramuscularly or intra-articular to treat cases of severe joint 
injury. The mechanism of action of PSGAGs has not been fully elucidated. In vitro 
studies show that PSGAGs do not affect the production of PGE2, but they can reduce 
NO production and the expression of inducible NO synthetase. They can also decrease 
the expression of MMP-1 and promote the synthesis of the central protein of aggrecan 
and procollagen type II. Chondroitin sulphate (CSP) and glucosamine are two oral 
glycosaminoglycans used in the treatment of equine OA. CSP is one of the main 
components of the extra cellular membrane of articular cartilage, on the other hand 
Glucosamine is a hexosamine precursor of the disaccharide unit of CSP and HA. 
Exogenous administration of these two molecules can prevent NO production, release 
proteoglycans and inhibit collagenase and gelatinase activity. Although controlled 
research has not been conducted on horses with natural disease, well-controlled 
clinical studies in humans with OA have been conducted.  
Considering OA has a multifactorial origin, where certain factors such as age, the 
conformation and mobility of the joint can influence the onset of the OA, the repercussion of 
these epidemiological factors can also have a significant effect on the effectiveness of the 
different products. 
Although the impact of epidemiological cofactors on the efficacy of OA treatments seems to 
be a justified hypothesis, few comparative studies have been conducted with conventional 
treatments, in order to correlate the efficacy of treatments with equine co-variables (age, 
lameness grade, joint, etc.) 
An ideal therapeutic approach should stop progressive loss of cartilage and stimulate the 
regeneration of damaged structures without (or with minor) adverse events. 
Treatments for equine joint diseases based on the intra-articular (IA) administration of 
mesenchymal stem cells (MSCs) are gaining importance because of their regenerative role.  
MSCs show significant potential for cartilage repair, which is attributed to their trophic and 
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3.2. Mesenchymal Stem Cells 
Mesenchymal stem cells are multipotent stromal cells that can differentiate into a variety of 
cell types, including osteoblasts (bone cells), chondrocytes (cartilage cells), myocytes (muscle 
cells) and adipocytes (fat cells). 
The International Society for Cellular Therapy (ISCT) proposes a set of standards to define MSC 
(Dominici et al., 2006) 
1. Plastic Adherence: MSCs must be plastic-adherent when maintained in standard 
culture conditions using tissue culture flasks. (figure 6) 
 
Figure 6: Equine Umbilical Cord Mesenchymal Stem Cell (EUC-MSC) 
 
2. Specific surface antigen (Ag) expression: according ISCT at least 95% of human-MSC 
population must express CD105, CD73 and CD90, as measured by flow cytometry. 
Additionally, these cells must lack expression (5/2% positive) of CD45, CD34, CD14 or 
CD11b, CD79a or CD19 and HLA class II. However, for MSCs derived from origins other 
than human, it is difficult to comply with the standards of the ISCT since some of the 
antigens cited above do not have equine cross-reactivity. In addition, there is a real 
lack of reagent specifically designed for equines in the biotechnological industry. For 
equine MSCs the surface antigen expression usually is limited to: CD45 (negative), 
MHC-II (negative), 79α (negative), CD90 (positive), CD44 (positive). 
 
3. Multipotent differentiation potential: the cells must be able to differentiate to 
osteoblasts, adipocytes and chondroblasts under standard in vitro differentiating 
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Figure 7: Equine Umbilical Cord Mesenchymal Stem Cells differentiated. A) Chondrogenic differentiation. B) Adipogenic 
differentiation. C) Osteogenic differentiation. 
 
Mesenchymal stem cells (MSCs) have been a focus in recent research because they are a 
potential tool in cellular therapies for several clinical applications. These cells can differentiate 
into mesenchymal lineages and secrete cytokines and growth factors with effects that favour 
the regeneration of damaged tissues. In addition, MSCs possess an immunoregulatory 
capacity that allows these cells to be used in the treatment of diseases with an important 
immune factor (Manferdini et al., 2013, Castro-Manrreza et al., 2015). 
MSCs can be isolated from different sources, most common being bone marrow (BM) and 
adipose tissue (AT). However, in the recent years umbilical sources are growing in popularity. 
Umbilical cord (UC) contains two umbilical arteries and one umbilical vein, both embedded 
within a specific mucous connective tissue, known as Wharton’s jelly (WJ), which is covered by 
amniotic epithelium. The isolation of fibroblast-like cells from WJ of human UC was reported 
by the first time by McElreavey et al., in 1991. (Nagamura-Inoue et al., 2014) 
Umbilical Cord source presents important advantages that made them a very interesting 
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i. Non-invasive extraction: The extraction of MSCs from the umbilical cord (both tissue 
and blood) occurs once the animal has been born and without interfering in the birth 
process, therefore it is considered a non-invasive process. This MSCs source avoids 
interfering with the animal and subjecting it to a painful procedure. Additionally, it 
avoids risks associated with the BM or AT extraction processes such as sedation, 
wound healing, etc. The non-invasive extraction of cells is an advantage in relation to 
animal welfare. (Nagamura-Inoue et al., 2014) 
 
ii. Isolation efficiency: The amount of mesenchymal stem cells, which can be obtained 
from bone marrow, is very limiting. Only 0.001 to 0.01% of mononuclear cells were 
reported, while 1 g of adipose tissue yields approximately 5 × 103 stem cells, which is 
500-fold greater than in the bone marrow. The isolation efficiency from Wharton’s 
jelly (WJ) is high and ranges from 1 to 5 × 104 cells/cm of umbilical cord. Side-by-side 
comparison of MSC from bone marrow adipose tissue and Wharton’s jelly 
demonstrated that WJ-MSC have highest proliferative capacity among tested cell types 
(Kalaszcynska et al., 2015). 
 
iii. Immunoprivileged status. The ability to modulate immunological responses ranks 
umbilical cord MSCs as an important compatible stem cell type for therapeutic 
applications in allogeneic setting. The mechanisms of immunoprivilege are still 
investigated; however, low MHC-I level and absence of MHC-II expression protect 
them from NK-mediated lysis. Despite the fact that they synthesize, though low, 
amounts of MHC class I, umbilical cord MSCs do not demonstrate immunogenicity. It 
can be attributed to the lack of co-stimulatory molecules-CD 40, CD80, CD86 
expression, and high levels of inhibitors of immune response: indoleamine- 2,3-
dioxygenase (IDO) and prostaglandin E2 (PGE2). Of particular importance is the fact 
that umbilical cord tissue MSCs express high levels of leukocyte antigen G6 (HLA-G6), 
the same which is produced by trophoblast and protects the embryo from immune-
based destruction (Kalaszcynska et al., 2015). In addition, recent studies in horses 
demonstrate that in MSCs from conventional sources (Bone Marrow) exist a great 
heterogeneity in the expression of MHC-II surface markers (range 0–98% positive) 
(Schnabel, 2013). In addition, a study from the same author (Schanabel et al., 2014) 
showed that the incidence of positiveness of MHC-II in bone marrow samples is about 
85%. However in our experience in more than 30 donors of Umbilical Cord MSC that 
has been characterized, all of them were strongly negative to MHC-II (<1%). 
 
iv. Low population doubling: Thanks to working with a tissue as rich in stem cells as the 
umbilical cord and the large anatomical size of an equine umbilical cord (~1kg), the 
number of stem cells obtained from a single umbilical cord is extremely greater than 
the one obtained from other sources. This greater number of cells in pass zero (P0) 
allows the expansion of the cells efficiently without the need to increase the cellular 
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duplications in excess. It is well known that as the cells are duplicated in culture, they 
lose differentiation capacity, immunomodulation and therapeutic actions (Crisostomo 
et al., 2006). 
 
v. Safety: Umbilical Cord MSCs are considered to be safer than other source due 
different reasons. On the one hand, being a tissue collected at the time of birth, the 
donor animal has not been exposed to the environment or infectious diseases, so the 
risk of infectious disease is much lower, being applicable only those of vertical 
transmission (Nagamura-Inoue et al., 2014). On the other hand, the cells are not 
exposed to the age or the environment of the donor, so the risk of genetic changes in 




3.2.1. Mesenchymal Stem Cell Mechanism of Action: 
After the discovery of the MSCs it was thought that their therapeutic activity was mainly due 
to their capacity for differentiation and on the functional integration after transplantation 
(Madrigal et al., 2014). However, in recent years it has been discovered that this capacity is 
certainly very limited. 
Currently it is considered that the main mechanism of action of MSCs is through paracrine 
actions both cell to cell and through the secretion of cytokines. 
MSCs engaged in a pro-inflammatory environment exert an anti-inflammatory and 
chondroprotective effect. (Manderfini et al., 2013; Manderfini et al., 2015; Saulnier et al., 
2004). 
Such anti-inflammatory capacity of MSCs is not only depended on the cell-to-cell contact, but 
also on their secreted paracrine factors (Najar et al., 2010). Many in vitro studies have shown 
their complex and wide range of anti-inflammatory/immunodulatory paracrine effects on 
adaptive immune system, including T and B-cells, dendritic cells and natural killers (Fontaine 
et al., 2016, Carrade et al., ,2014). 
It has been postulated by the scientific community that the MSCs capacity of PGE2 secretion is 
a key factor in MSC immunoregulatory function. (Chen et al., 2010; Najar et al., 2010; 
Solchaga et al., 2012; Carrade et al., 2014; Fontaine et al., 2016). Therefore, the MSCs ability 
to secrete PGE2 turns into an important cellular aspect for MSC Mechanism of Action MoA. 
MSCs are very potent immunomodulatory and anti-inflammatory agents. In fact, many 
publications have reported the suppression of alloantigen proliferation in Mixed Lymphocytes 
Reaction (MLR) when MSCs isolated from human and other mammalian species (including 
baboon, canine, caprine, equine and rodents) are co-cultivated/stimulated with active 
peripheral blood mononuclear cells (PBMCs), especially T-cells. This suppression is confirmed 
to be PGE2-mediated since the PBMC proliferation is restored after the PGE2 production 
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blockage (Nicola et al., 2002; Aggarwal et al., 2005; Chen et al., 2010; Carrade et al., 2012;, 
Solchaga et al., 2012 Carrade et al., 2014; Auletta et al., 2015; Ayalla-Cuellar et al., 2017). 
This inhibition capacity of PBMCs proliferation has been tested in the EUC-MSCs used in the 
present study. 
Although the purpose of this work is not to deepen in the pharmaceutical development that 
involves transforming cells extracted from umbilical cord in a medicine fulfilling all the 
European quality requirements (Good Manufacturing Practices, European Pharmacopoeia, 
European Guidelines, etc.) different in vitro studies have been developed by our group, to 
discover the mechanism of action of EUC-MSCs. 
During the pharmaceutical development, special importance was given to the research on the 
mechanism of action (MoA) of the EUC-MSC. 
As part of this investigation, the EUC-MSCs were stimulated with synovial fluid extracted from 
horses with OA and associated clinical symptoms (lameness). Due to the stimulation with the 
inflammatory environment of the synovial fluid the secretion capacity of PGE2 by EUC-MSCs 
was increased 23-fold compared with the capacity of secretion without stimulation with 
synovial fluid (Figure 8). 
 
 
Figure 8: PGE2 secretion by EUC-MSC with or without stimulation with synovial fluid from OA lame horses 
 
In addition Equine Umbilical Cord Mesenchymal Stem Cells used in this work have also 













  Page 30 of 114 
demonstrated to be one of the main responsible of this action (Figure 9). In this in vitro assay 
EUC-MSCs were co-cultured with PBMCs previously activated with Phytohemagglutinin (PHA) 
for 6 days. It was observed that EUC-MSCs were able to inhibit the PBMCs proliferation and 
that the inhibition was mediated by PGE2, since this could be restored in PGE2 secretion was 
blocked by indomethacin (INDO). 
 
Figure 9: MRL: Activated equine PBMCs are suppressed by EUC-MSC 
 
Therefore PGE2 has been postulated as one of the main cytokines responsible of the paracrine 
actions of the EUC-MSC and highlight as an excellent marker of efficacy. 
 
3.2.2. Prostaglandine E2: 
Prostaglandins are lipid autacoids derived from arachidonic acid. They both sustain 
homeostatic functions and mediate pathogenic mechanisms, including the inflammatory 
response. They are generated from arachidonate by the action of cyclooxygenase (COX) 
isoenzymes and their biosynthesis is blocked by nonsteroidal anti-inflammatory drugs 
(NSAIDs), including those selective for inhibition of COX-2.  
PGE2 is one of the most abundant PGs produced in the body, is most widely characterized in 
animal species, and exhibits versatile biological activities. Under physiological conditions, 
PGE2 is an important mediator of many biological functions, such as regulation of immune 
responses, blood pressure, gastrointestinal integrity, and fertility. Dysregulated PGE2 
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synthesis or degradation has been associated with a wide range of pathological conditions. In 
inflammation, PGE2 is of particular interest because it is involved in all processes leading to 
the classic signs of inflammation: redness, swelling and pain. Redness and oedema result from 
increased blood flow into the inflamed tissue through PGE2-mediated augmentation of 
arterial dilatation and increased microvascular permeability.  
Generally, this soluble factor is recognized as a mediator of active inflammation; however, the 
interest in its immunosuppressive ability is growing since it has been widely demonstrated to 
suppress both innate and antigen-specific immunity at multiple molecular and cellular levels, 
“earning PGE2 the paradoxical status of a pro-inflammatory factor with immunosuppressive 
activity” (Kalinski, 2012). 
In fact, multiple publications support that PGE2 plays a critical role in the anti-inflammatory 
effect of MSCs on PBMC modulation (Siegel et al., 2009; Krampera, 2011; Bao et al., 2011; 
Yanez et al., 2010; Manderfini et al., 2013; Manderfini et al., 2015). 
 
Effect of PGE2 in cells: 
PGE2 affects many of the cells present in the development of OA. The effect of PGE2 in the 
different cell types present in the OA infiltrates have been summarized below: 
I. Macrophages (M): these cells are classified in two groups: M1 and M2. M1 are 
activated by pro-inflammatory Th1 cytokines, as IL-1, IL-12, INF-γ and TNF-α, and M2 
produce anti-inflammatory cytokines, such as TGF-β and IL-10. The main form of 
macrophages in pro-inflammatory environment is the M1 one.  
Numerous studies have demonstrated that MSCs lead the macrophage phenotype 
towards M2, which involves the decrease of TNF-α, IL-1, IL-6 and IL-12 production and 
the enhancement of IL-10 (anti-inflammatory). In fact, this ability of MSCs to 
reprogram the cells has been proven to be mediated not only by high level of PGE2 
secreted by active MSCs, but also by constitutive PGE2 level of non-active MSCs. (Kim 
et al.,2009; Maggini et al., 2010 and Fontaine et al., 2015) 
II. T-cells:  
o T-helper cells (Th): PGE2 at high doses inhibits IL-2 release (pro-inflammatory) 
and IL-2 responsiveness in T-cells, non-specifically suppressing T-cell activation 
and proliferation. In contrast at much lower PGE2 concentrations polarize CD4+ 
T-cells from aggressive Th1 cells (promoting the inflammatory / cytotoxic form 
of immunity) towards Th2 and Th17, which are less destructive. This effect is 
regulated by suppressing production of Th1 cytokine IFN-γ and IL-12 
(responsible of the pro-inflammatory M1 macrophages) and by promoting the 
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production of IL-4 and IL-5 (Aggarwal et al., 2005; Kalinski, 2013; Ayala-Cuellar 
et al., 2017 and Dutton et al., 2018). 
o Citotoxic T-cells (Tc): PGE2 inhibits Tc activity and suppresses their ability to 
interact with their targets (Kalinski, 2013). 
o T-regulatory cell (Treg): multiple studies have demonstrated that PGE2 
enhances the differentiation of Treg with suppressive activity, like Foxp3+ Treg. 
In fact, the content of Foxp3+ Treg was elevated in MLR with a significantly 
MSC mediated T-cell suppression and an increment of PGE2 level (Auletta et 
al.,, 2015; Ayala-Cuellar et al., 2017; Kalinski, 2013) 
III. B-cell: PGE2 interferes with the early phase of B-cell activation regulating the process 
of Ig class switch in activated B cells and suppressing the cytokine and antibody 
production (Kalinsky, 2013).  In fact, the co-culture of B-cells with MSCs results in a 
decrease of B-cell proliferation, differentiation to IgM, IgG and IgA-producing cells and 
expression of CXCR4, CXCR5 and CCR7 (major chemokines involved in the B-cell 
homing) (Cocione et al., 2006 and Traggiai et al., 2008). 
Moreover, apart from immunosuppression of adaptive immune system, MSCs in co-culture 
with inflamed human synoviocytes and chondrocytes have shown decrease in the expression 
of IL-1β, IL-6 and IL-8 in both cellular lineages. In addition, it was also observed that significant 
down-modulation of other chemokines and metalloproteinases promote the progression of 
the disease (CXCL1, CCL2, CCL3, CCL5 ADAMTS4, ADAMTS5 and MMP13), as well as, the up-
regulation of TIMP1, tissue inhibitor of metalloproteinases. 
In particular, the role of COX-2 and PGE2 has been demonstrated since the expression of COX-
2 (inducible enzyme involved in the PGE2 synthesis) is down-regulated in inflamed 
chondrocyte and synoviocyte monocultures that produced high levels of pro-inflammatory 
factors. Likewise, PGE2 released in co-cultures with MSCs have been shown higher than in 
monocultures.  
Once again, these data show the key role of PGE2 in the immunesuppressive properties of 
MSCs, in particular on inflamed chondrocytes or synoviocytes, since the COX-2 inhibition in 
them was related to PGE2 increase after MSC co-incubation (Manderfini et al., 2013, 
Manderfini et al., 2015). 
The relation between PGE2 and immune cells, chondrocytes and synoviocytes is summarised 
in Figure 10. 
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Figure 10: PGE2 Effect of PGE2 secreted by MSC in immune cell, chondrocytes and synoviocytes 
 
3.2.3. Rational use of MSC in equine OA: 
OA physiopatogenesis and EUC-MSC MoA has been summarised in Figure 11, that briefly can 
be resumed as:  
Age, genetic factors, or microtraumas cause damage to the equine joints. This repeated 
damage generates an inflammatory response in the joint and immune cells (specially Tcell and 
Macrophages) infiltrate the joint. In addition, synovicytes of the synovial membrane are 
activated as a reaction to the damage and the immune infiltrate. 
Both, immune cells and synoviocytes, react secreting inflammatory cytokines such us TNF-α, 
IL-1β and IL-6.  
These inflammatory cytokines (mainly TNF-α and IL-1β) alter the homeostasis of chondrocytes 
provoking the degradation of the extracellular matrix. This degradation provokes the release 
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of matrix degradatory proteases, mainly metalloproteases (MMP) that increase the 
inflammatory environment of the synovial fluid.  
Therefore, the OA could be considered as a circle of negative feedback where each one of 
those involved (immune cells, synoviocytes and chondrocytes) respond to the damage by 
enhancing the negative effects that favour the evolution of the disease, the inflammatory 
environment and joint degeneration. 
This inflammatory environment leads to clinical sings in the horse, mainly lameness grade, 
flexion pain, and sometimes joint effusion. 
An adequate strategy for OA treatment is to work in the two key points involved in the 
disease and its progression: the inflammatory infiltrate and the inflammatory cytokines and 
degradative proteases release to the joint environment. Products intended to treat OA should 
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Figure 11: PGE2 relation with EUC-MSC MoA 
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Equine Umbilical Cord MSC and equine clinical improvement: 
As previously explained, equine OA is associated with clinical symptoms in horse, 
mainly lameness, joint effusion and flexion pain, but also reduced sport performance 
and abilities. Being the lameness the most limiting symptom of OA, is lameness where 
products against OA are focused. 
It has been established, that among other inflammatory cytokines, the main reason of 
lameness grade in horses is the increase of TNF-α and MMP (Ma et al., 2017). 
In order to scientifically establish a reasonable cause effect between EUC-MSCs´ 
treatment and equine clinical symptoms improvement (lameness reduction), the effect 
caused by MSCs on TNF-α and MMP should be probed, since they are linked with the 
in vivo efficacy: Lameness reduction. 
 
Figure 12: Relation between OA-Clinical Signs-MSC- Efficacy 
 
It has been proven that EUC-MSCs from Wharton´s Jelly in co-culture with activated 
PBMCs cause PBMCs proliferation inhibition (Figure 9). 
Also Carrade et al. (2014) demonstrated Tcell proliferation inhibition and a decrease of 
the secretion of TNF-α and other inflammatory cytokines in a Mixed Lymphocyte 
Reaction (MLR) model with Equine Umbilical Cord MSC. Carrade work also 
demonstrated that this anti-inflamatory effect was PGE2 mediated, as when PGE2 
secretion was blocked, the Tcell proliferation and TNF-α secretion was restored 
(Carrade et al., 2014).  
On the other hand, Saulnier et al. (2014) developed an in vivo and an in vitro research 
with Equine Umbilical Cord Mesenchymal Stem Cells. In the in vitro model, the effect 
of MSC in synociocytes was investigated. It was demonstrated that if synoviocytes 
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were put in direct contact with the cultured medium of EUC-MSCs (that contained all 
the soluble factors secreted by MSC) synoviocytes expressed significant less MMPs. 
The beneficial effect of Equine Umbilical Cord Mesenchymal Stem Cells has been 
strongly demonstrated in the reduction of cell infiltrated (Tcell), the reduction of TNF-α 
and the reduction of MMP. In addition, it was demonstrated that the main responsible 
for this action is mediated by the secretion of PGE2 by EUC-MSC. 
Therefore, the lameness grade reduction in horses with OA by the treatment with EUC-
MSCs has been established based on the reduction of inflammatory cells infiltrated 
and the reduction of inflammatory cytokines (TNF-α) and matrix degradation proteases 
(MMP). In addition, it has been demonstrated that this effect is PGE2 mediated. 
 
3.3. Clinical trials in veterinary medicine 
In order to demonstrate the efficacy of veterinary medicines, clinical trials must be 
conducted in a well manner that allows the scientific community to reach solid 
conclusions in terms of efficacy and safety of new products. 
Clinical trial is defined as a research study in which one or more subjects are 
prospectively assigned to one or more interventions (which may include placebo or 
other controls) to evaluate the effects of those interventions on health-related 
biomedical or behavioural outcomes. 
The purpose of clinical trials is to demonstrate or substantiate the effect of the 
veterinary medicinal product after administration at the proposed dosage regimen via 
the proposed route of administration and to specify its indications and 
contraindications according to species, age, breed and sex, its directions for use as well 
as any adverse reactions which it may have (Directive 2001/82/EC) 
Different regulatory bodies work helping researchers on how clinical trials must be 
designed and conducted if the intention is to submit the results for the approval of a 
new product as a veterinary medicine. There are public guidelines at national level 
(Agencia Española de Productos Sanitarios (AEMPS)) or at international level 
(European Medicine Agency (EMA)). Several guidelines exist to guide researchers in 
the design of veterinary clinical trials for regulatory purposes of which the below can 
be highlight: 
 VICH GL9 - Good Clinical Practice (June 2000): which provides guidance on the 




  Page 38 of 114 
 Directive 2001/82/EC on the Community code relating to veterinary medicinal 
products. 
 Guideline on statistical principles for Clinical Trials for veterinary medicinal 
products (pharmaceuticals)" of 16 January 2012 (EMA / CVMP / EWP / 
81976/2010): This document provides guidance on the statistical principles to 
be considered in the design, conduct, analysis and evaluation of clinical trials to 
demonstrate efficacy and/or safety of an investigational veterinary 
pharmaceutical product in animals. 
For obtaining a Marketing Authorisation (MA) as veterinary medicine, quality in the 
manufacturing, safety and efficacy of the product must be demonstrated to the 
authorities. In order to demonstrate safety and efficacy a well-designed clinical trial 
must be submitted. 
If the intention of the researcher is to use the data to obtain a Marketing 
Authorisation, regulatory guidelines must comply from the early beginning (design of 
the trial) to the end of the clinical phase (data analysis). 
Different types of clinical trials could be conducted depending on the final objective. 
One classification for clinical trials could be: observational or interventional. 
In observational studies, participants are identified as belonging to study groups and 
are assessed for biomedical or health outcomes. Participants may receive diagnostic, 
therapeutic, or other types of interventions, but the investigator does not assign 
participants to a specific interventions/treatment. This kind of clinical trial provides 
less compelling evidence than interventional clinical trials.  In observational studies, 
the investigators retrospectively assess associations between the treatments given to 
participants and their health status, with potential for considerable errors in design 
and interpretation. This kind of clinical trial is usually used in a post marketing phase or 
in specific populations groups (pregnant, infants, etc.) but not as a single clinical trial 
for obtaining a Marketing Authorisation.  
In interventional studies, participants are assigned to groups that receive one or 
more interventions/treatments (or no intervention) so that researchers can evaluate 
the effects of the interventions on biomedical or health-related outcomes. The 
assignments are determined by the study's protocol.  
Interventional studies are the most common types of studies conducted in the 
pharmaceutical industry. Different types of interventional studies could be conducted 
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Well design interventional studies should be:  
Controlled clinical trials: Clinical trials which involve one or more test treatments and 
at least one control treatment. Controlled trials have specified outcome measures for 
evaluating the studied intervention, and a bias-free method for assigning patients to 
the test treatment. Depending on the product use in controlled clinical trials different 
types could be performed: 
 Negative Control: This is a trial with the primary objective of showing that the 
response to the investigational product is superior to a comparative agent: 
placebo or non-treatment.  
 Positive Control: In this trial the primary objective is showing that both 
products have comparable efficacy (Non-inferiority). In this kind of design 
usually the comparator used is the conventional treatment and the new 
product wants to demonstrate that the efficacy and safety is at least the same 
as the one observed in conventional treatments. The comparator in this kind of 
clinical trials is always an active molecule. 
 Historical Controls: where old data is used to compare with new data from new 
trials. A historical control group should be chosen so that the trial’s endpoints 
are comparable. If the controls are not carefully chosen so that they are 
reasonably compatible with the experimental group, this can result in 
inaccurate results.   
Design: depending on how the treatment is allocated into the patients, different kinds 
of clinical trials can be defined: 
 Cross-over assignment: A type of intervention model describing a clinical trial in 
which groups of participants receive two or more interventions in a specific 
order. For example, two-by-two cross-over assignment involves two groups of 
participants. One group receives drug A during the initial phase of the trial, 
followed by drug B during a later phase. The other group receives drug B during 
the initial phase, followed by drug A. So, during the trial, participants "cross-
over" to the other drug. All participants receive drug A and drug B at some 
point during the trial but in a different order, depending on the group to which 
they are assigned. 
 Parallel: A type of intervention model describing a clinical trial in which two or 
more groups of participants receive different interventions. For example, a 
two-arm parallel assignment involves two groups of participants. One group 
receives drug A, and the other group receives drug B. So, during the trial, 
participants in one group receive drug A "in parallel" to participants in the 
other group, who receive drug B. 
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Masking: A clinical trial design strategy in which one or more parties involved in the 
trial, such as the investigator or participants, do not know which participants have 
been assigned which interventions. Types of masking include: open label, single blind 
masking, and double-blind masking. 
 Open Label: there is no masking. All people involve in the study know the 
treatment received. 
 Single blind: some people involve in the study is blind but other are not blind 
e.g. the researcher knows the product allocated but the owner is blind. 
 Double blind: All people involve in the study is blind (researcher and owner do 
not know the treatment received).  
Site: depending on how different place the trial is conduct: 
 Multicentric: the same clinical trial (same protocol of study) is conducted in 
different places with different researchers and different epidemiologic 
circumstances. In veterinary medicine for example the design of multicentric 
clinical trials for antimicrobials or anthelmintic is especially important since the 
resident microbiota could differ from one location to another. In pathologies 
where the location, climate or endemic microbiotics have no impact, the need 
for a multicentric design may not be a priority. 
 Single place: only one centre is used. Patients and researchers come from the 
same place. This type of clinical trials is necessary when, for example, highly 
specialized machinery is used that is not present in other centres. In non-
infectious diseases, where the epidemiology of the disease is comparable 
everywhere, this type of design does not involve large bias. 
In addition to the design, other important aspects of the clinical trial are relevant to 
the final outcome. One of these key points is the Primary Endpoint Selection. 
Primary Endpoint is defined as an event or outcome that can be measured objectively 
to determine whether the intervention being studied is beneficial or not.  
Usually, the primary endpoints are assigned as qualitative classification “yes” or “no” 
to identify whether the treatment has been beneficial or not (e.g.: the animal has 
stopped convulsing yes / no). 
At the time of the statistical calculation, the number of patients who have reached the 
objective established in the primary endpoint in each group is compared to identify the 
efficacy or lack of. 
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For primary endpoint selection the intended efficacy of the product must be well 
known in order to establish an adequate endpoint that shows the benefits of the 
investigated medicine and gives a clinical relevance result to the animal.  
Often preliminary exploratory clinical trials are developed in a small number of animals 
in order to determinate an adequate primary endpoint in confirmatory clinical trials. 
The final objective of this work is to submit the data to the European Medicine Agency  
(EMA) in order to obtain the Marketing Authorisation of Equine Umbilical Cord 
Mesenchymal Stem Cells as veterinary medicine. 
With the intention to demonstrate the efficacy and safety of Equine Umbilical Cord 
Mesenchymal Stem Cells in equine OA, a well conducted clinical trial has to be 
designed and conducted in accordance with regulatory guidelines (VICH GL9). 
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4. OBJECTIVE AND JUSTIFICATION 
4.1.1. Objective 
The objective of this work is: 
 To demonstrate the efficacy of Equine Umbilical Cord Mesenchymal Stem Cells 
(EUC-MSCs) in horses with clinical signs associated with mild to moderate 
Osteoarthritis (OA). 
 To demonstrate the safety of EUC-MSCs in horses with clinical signs associated 
with mild to moderate Osteoarthritis (OA). 
 To investigate the effect of co-variables in the efficacy of EUC-MSC 
 To compare the efficacy and safety of EUC-MSC with conventional treatments 
4.1.2. Justification of the study 
As deeply explain before Osteoarthritis (OA) is a major cause of reduced athletic 
function and retirement in equine performers. With a prevalence as high as 80%, OA is 
the most common cause of lameness in horses, being responsible for 60% of total 
cases, and one of the most frequently responsible for premature abandonment of the 
sport life (Souza, 2016).  
However, despite the high prevalence and the devastating consequences that have for 
the equine sector with an economic impact valued at 18,000 million € in Europe, the 
pharmaceutical industry has not provided new solutions or innovative therapeutic 
alternatives for decades. 
Medical treatment of OA may include anti-inflammatory and analgesic drugs to reduce 
the inflammation and pain, an intra-articular administration of corticosteroids, 
administration of NSAIDs and nutritional supplements that purportedly improve joint 
function (Souza, 2016). However symptomatic treatments but are not able to stop the 
disease and are also associated with long-term side effects. 
During this work it will investigate the efficacy and safety of EUC-MSCs, their 
effectiveness depending on different epidemiological cofactors such as age, physical 
activity, etc. and a comparison will be made with the efficacy and safety of 
conventional treatments. 
This work has been carried out to investigate EUC-MSCs since they could represent an 
innovative therapeutic alternative to conventional treatments. 
 
 

























5. MATERIAL AND METHODS  
 
MATERIAL AND METHODS 
 
  Page 45 of 114 
5. MATERIAL AND METHODS 
5.1. Study design 
5.1.1. Type of study and overall study design 
A comparative superiority study, multicentric, parallel, blinded, randomized and 
placebo-controlled Clinical Trial was designed. The study was carried out complying 
with the Good Clinical Practice guidelines (VICH 9 guidelines). 
The study was conducted in two groups Group 1 (treated group) and Group 2 (control 
group). 
The owner of all the animals enrolled signed an Informed Consent before the 
enrolment of the animal and the risk and benefits as well as the objective of the trial 
were explained to the owner. 
Group 1: Treated group; Horses (n=36) were tested with Equine Umbilical Cord 
Mesenchymal Stem Cells. 
Group 2: Control group; Horses (n= 39) were tested with placebo. 
The study was designed and conduct according to the schedule that follows: 
Activity 
Pre treatment  










Checking the inclusion 
criteria 
X X     
Informed consent  X     
Diagnosis X      
Blood Analysis  X  X   
Intra-articular treatment  X     
Physical exam X X X X X X 
Orthopaedic examinations X X  X X X 
Registration Adverse Events  X X X X X 
Injection site evaluation  X X X X X 
Study completion      X 
Table 2: Tabulated summary of the study outline 
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Before starting the Clinical Trial, a single list of randomisations for the whole trial was 
developed. 
Horses were randomly assigned to Treatment or Placebo Group according to the 
randomisation list developed. 
The randomisation list was developed manually by a non-blinded person by flipping a 
coin, where head was code A (Treatment) and Tail was code B (Placebo).  
None (demographic, symptomatology, etc) criteria were applied for the development 
of the Randomisation list. The list was developed strictly aleatory and before the 
clinical trial began. 
5.1.2. Blindness 
Investigators, study personnel and owners were blinded to Treatment or Placebo. 
Both the Treatment and the Placebo were conditioned in identical-looking vials. 
Considering Mesenchymal Stem Cells have a particularly cloudy colour, difficult to 
mask, the syringe used was covered with opaque material before sterilizing, to ensure 
completely blindness of the researcher (Figure 10). 
 
Figure 13: Syringe with opaque material for ensuring the blindness 
 
In order to ensure full blinding of the investigator, the presence of a dispenser was 
designed. The dispenser was a person, unknown to the investigator, who was 
responsible for handling sterile vials and syringes to prevent that the researcher could 
detect if the product was treatment or placebo during the manipulation of the vials. 
The researcher applied the product to the horse, previously prepared by the dispenser.  
In addition, different measures were adopted in order to avoid bias: 
- In each horse observations were carried out by the same person and 
instruments. 
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- Housing conditions were similar for both groups (experimental and control) in 
each location.  
- The researchers did not know the identity of the experimental and control 
groups (blinded study). 
 
5.2. Treatment and administration 
The product used in the trial, is non-toxic and non-harmful for human beings. 
Nevertheless, farmers, veterinarians and researchers were informed of the 
characteristics of the products.  
Investigational Veterinary Product (IVP) 
Name of the IVP:  EUC-MSC (HorStem®) 
Description:   Sterile injectable suspension conditioned in sterile vial, sealed, 
tight and penetrable for syringes 
Composition per one dose (1 ml):  
Active ingredients:  Equine Umbilical Cord Mesenchymal Stem Cells  15 million (± 
20%) with a viability ≥70% 
Excipient:  Confidential formula  1 mL 
Control product Placebo: 
Name of the Control Product: Placebo 
Description:   Sterile injectable suspension conditioned in sterile vial, sealed, 
tight and penetrable for syringes 
Composition per one dose (1 mL):  
Active ingredients:  None 
Excipient:  Saline solution 1 mL 
 
Method and route of administration: 
Before administration of the VIP or Placebo, the joint was prepared by cleaning the 
area with an antiseptic soap (alternate washes, betadine or chlorhexidine / alcohol for 
at least 2 minutes) to reduce the number of bacteria at the injection site. The hair was 
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not clipped unless the horse was particularly dirty, hairy, or if anatomic landmarks 
were difficult to identify.  
Before aspiration into the syringe the content of the vial was homogenized with gentle 
movements, this procedure was done by the dispenser in order to maintain blindness. 
Next, immediately prior to inserting the needle (20G) into the joint (arthrocentesis), 
the area was generously cleaned with alcohol until the area was free of soap. At that 
point, the needle (without the syringe attached) was quickly and easily inserted intra-
articularly. 
Due to anatomical differences among individual horses' joints, it was allowed that the 
veterinarian redirected the needle until it was fully inside the joint and synovial fluid 
was (typically) visible in the hub of the needle. The opaque syringe was subsequently 
attached to the needle and the drug of choice was delivered directly into the joint 
space. 
After the arthrocentesis and the product administration, a bandage was applied (if 
applicable) to the area for 24h, with the intention of preventing dirt in the injection 
site. 
The bandage consisted of a softly applied cotton band followed by a bandage (non-
compressive) with a cohesive bandage. 
 
5.3. Diagnosis of OA:  
The diagnosis of OA was made by each researcher. The final diagnosis is the result of 
the different diagnosis tools that allow having an overall conclusion to issue a final 
diagnosis.  
Detailed description of the diagnostic procedure: 
a) Palpation of the joint 
Once the lameness was evaluated, palpation of the lame limb was performed 
(this is normally performed before trotting the horses). Examination of both 
soft tissues and joints on the lame limb was performed checking for signs of 
inflammation, joint distension, pain on deep palpation or increased size of soft 
tissue structures.  
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Figure 14: Example of limb palpation 
 
b) Lameness examination 
With the objective to detect gait irregularities or lameness in the animal and 
according to American Association of Equine Practitioners (AAEP) guidelines the 
horse was trotted and walked in straight line and in circles in both hard and soft 
ground. The horse was observed from the front, back and both side views.  
c) Flexion test 
According to the AAEP guideline the veterinarian holds the horse's limbs in a 
flexed position and then releases the leg. As the horse trots away, the 
veterinarian watches for signs of pain, weight shifting or irregular movement. 
Flexing the joints in this manner may reveal problems not otherwise readily 
apparent (Figure 15). 
 
Figure 15: Example of a flexion test 
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d) Perineural Block 
Perineural blocks consisted in the subcutaneous or perineural injection of local 
anaesthetic (mepivacaine, lidocaine, etc) in the intention to block the pain 
sensation in the area. Working systematically, the veterinarian temporarily 
deadens sensation to specific segments of the limb, one region at a time, until 
the lameness disappears. When the lameness disappears it is considered that 
the anatomical structure that causes lameness is in the area of action of the 
blockage (Figure 16). 
 
Figure 16: Example of perineural block. In blue it is represented the pain area of each block 
e) Radiology 
Once the region of pain was localised with palpation, flexion pain test and 
perineural blocks, radiographs of the area were taken making as many 
projections as necessary to make a diagnosis. 
f) Intra-articular anaesthetic block (IAAB) 
Once these diagnosis tools were done, usually a joint was selected as the cause 
of lameness. At this point an intra-articular anaesthetic block (IAAB) was 
performed (note that the IAAB was always done in a different day than 
perineural blocks) in order to localise the source of pain to the joint. For IAA 
blocks an anaesthetic (mepivacaine, lidocaine, etc) is introduce inside the joint. 
After ~5 minutes if the pain is located inside the joint the horses should stop 
limping. 
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If the IAAB showed a clear improvement of the pain and radiography signs of OA were 
detected with no other changes compatible with soft tissue pathology a diagnosis of 
OA in that joint was made. 
The compliance of all the detail tools listed below is the gold standard for diagnosis in 
equine practice, and has been widely reported in clinical trials. (Lynn et al., 2004; 
Cayzer et al., 2011; Tnibar et al., 2016.). 
In the figure below is represented, as an example, how to perform a diagnosis of distal 




Figure 17: Image of a typical diagnosis during the clinical trial for distal joints 
 
Only horses with clinical sings in a single joint per leg were included. Horses with 
clinical signs in more than one joint per leg (e.g. proximal and distal joint in the right 
forelimb), which present improvement after anaesthetic block of one joint (e.g.: distal 
joint), but still maintain a lameness degree corresponding to the other affected joint 
(e.g.: proximal joint), have not been included in the study. 
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Horses with bilateral diagnosis and clinical symptoms (in contralateral limbs) could be 
included in the present study, however only the joint which manifests a greater 
lameness degree was medicated. Bilateral horses showing no clear limp lameness 
presenting bilateral shortening stride have not been included in this study. 
The diagnosis had to ensure the following information: 
- The horse had radiological signs of mild to moderate according to the scale of 
Cornelissen Radiographic Scale (adapted to other joints) (Table 2) 
- The clinical symptoms (lameness, flexion pain and effusion) met the inclusion 
criteria of the protocol. 
- The clinical symptoms corresponded only to the affected joint by OA. 
- The horses had no other pathologies underlying that may alter the results. 
 
Radiographic Scale 
Score Radiographic findings 
0 Rounded joint margins. No subchondral bone sclerosis. No signs of anomalies 
1 Pointed joint margins of the joint or minimal localized subchondal bone sclerosis 
2 Small spur(s) on joint margins or mild localized subchondal bone sclerosis 
3 Moderate spur(s) on joint margins or mild localized subchondal bone sclerosis 
4 Large spur(s), severe subchondal bone sclerosis, cyst, osteochondral fragments or evidence of joint space narrowing. 
Table 3: Cornelissen Radiographic Scale adapted to all joints (Cornelissen 1996) 
 
 
5.4. Orthopaedic examinations:  
Once between day -15 and -7, days 0, 14 (±2), 35 (±2) and 63 (±2), the enrolled animals 
were Orthopaedic examined of the next parameters:  
 Assessment of lameness according to the American Association of Equine 
Practitioners (AAEP) guideline. The use of half points was allowed when the 
lameness grade of the horse was between two integer values. The use of half 
points in the lameness scale increases its precision, making it a more suitable 
scale for clinical studies where lameness is the primary efficacy endpoint, and 
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therefore it is necessary to determine the improvement in the most reliable 
and precise way possible (Keegan et al., 2009, Back et al., 2007, Hu et al.,, 2009, 
Erket et al., 2004, Schneider, 2013) 
AAEP Lameness Scale 
0 Lameness not perceptible under any circumstances. 
1 
Lameness is difficult to observe and is not consistently apparent, regardless of circumstances (e.g. under 
saddle, circling, inclines, hard surface, etc.). 
2 
Lameness is difficult to observe when trotting in a straight line but consistently apparent under certain 
circumstances (e.g. weight-carrying, circling, inclines, hard surface, etc.). 
3 Lameness is consistently observable at a trot under all circumstances. 
4 Lameness is obvious at a walk. 
5 Lameness produces minimal weight bearing in motion and/or at rest or a complete inability to move. 
Table 4: AAEP Lameness score (Scale of the American Association of Equine Practitioners AAEP). The use of half 
points was allowed when the lameness grade of the horse was between two integer values. 
  Assessment of joint effusion according the following table: 
Joint Effusion Scale 
0 No Swelling 
1 Mild Swelling 
2 Severe Swelling 
Table 5: Joint Effusion Score 
 Assessment of flexion pain according to the following table: 
Flexion Test Scale 
0 No flexion response 
1 Mild flexion response 
2 Moderate Flexion response 
3 Severe flexion response 
Table 6: Flexion Pain Score 
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5.5. Physical examinations:  
Physical exploration was always performed by the veterinarian and consisted of a 
general medical examination, where the following actions should be performed: 
 Cardiac and pulmonary auscultation 
 Abdominal auscultation (peristalsis) 
 Lymph nodes palpation 
 Revision of the general state (hydration, corporal condition, lachrymation, nasal 
discharge) 
 Inspection of the skin and the injection point 
 Rectal body temperature 
The physical examination was performed once between day -15 and -7, days 0, 1, 14 
(±2), 35 (±2) and 63 (±2).  
The results of the physical examinations were described as normal (physiological 
parameters e.g. rectal temperature between 37ºC and 38ºC) or abnormal. Those 
abnormal or non-physiological values were investigated case by case and included as 
an adverse event if applicable. 
5.6. Laboratory examinations:  
The laboratory examinations were outsourced in a specialist veterinary clinical analysis 
laboratory. 
Before inclusion (Once between day -15 and day 0) and at day 62 (±2) blood samples 
were collected for haematology and serum chemistry. 
Haematology: Haematies, Haemoglobin, Haematocrit, Medium Corpuscular Volume, 
Leucocytes, Platelets, Eosinophil, Basophils, Lymphocytes, Monocytes, and cytology of 
the blood cells. 
The serum chemistry: Urea, Creatinine, AST, ALT, Total Protein, Alkaline phosphatase, 
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5.7. Inclusion, exclusion and post-inclusion removal 
5.7.1. Inclusion criteria 
Horses diagnosed with OA and with clinical symptoms associated as lameness and 
flexion pain were included. 
Animals that met the criteria of the list were included: 
 Healthy (except of OA) mature horses. 
 Animals with radiological signs of mild to moderate degenerative joint disease. 
1, 2 and 3 degrees on the scale of Cornelissen 1996 adapted to all joints (Table 
3). 
 Animals with signs of lameness Grades 1, 2 and 3 (Table 4) 
 Animals with joint effusion Grades 0, 1 and 2 (Table 5) 
 Animals with Flexion Pain Grades 1, 2 and 3 (Table 6) 
 The sum of the three clinical signs (lameness, joint effusion and flexion pain) 
between 4 and 7 points, inclusive. 
 Animals clearly may respond, at the field investigator criteria, to the intra-
articular anaesthetic joint block 
 Animals whose lameness has remained stable for at least 4 weeks prior to the 
inclusion of animal 
 Animals who have not received intra-articular medication in the last three 
months 
 Animals who have not received systemic medication in the last 15 days 
 Patients without intra-articular free fragment (joint chip) 
 
5.7.2. Exclusion criteria 
 Animals with signs of joint infection 
 Bilateral horses showing no clear limp lameness presenting bilateral 
shortening step. 
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 Horses with lameness produced by more than one joint per limb. 
 Animals whose indication is surgical rather than medical 
 Animals with any other disease (e.g. concomitant injuries (e.g. Laminitis, 
lymphangitis, associated ligament injuries, etc ...) that could require the 
administration of anti-inflammatory drugs or other medications not 
permitted during the study 
 Animals with presence of a free fragment articular 
 Horses who have been introduced to any change in routine ride, rider, 
horseshoes, and type of training that can help or hinder its clinical course 
or mask test results 
 Animals with open wounds in the joint to be treated 
 Pregnant or lactating mares  
 Animals destined to enter the food chain  
 Animals that have received intra-articular medication in the last three 
months 
 Animals that have received systemic medication in the last 15 days 
 
5.7.3. Post-inclusion removal criteria   
Criteria for removal   
 The inclusion in this study was voluntary, and therefore an animal may be 
withdrawn if its owner wishes at any time during the test 
 Animals in whom a serious adverse event, such as colic, accident, requiring 
treatment not allowed which makes it incompatible to continue in the 
study 
 Animals where the evolution of degenerative joint disease worsens 
markedly and it is necessary to administer additional rescue medication 
 Animals unable to properly fulfil the plan set out in the protocol plans 
 Animals who needed to implement any changes in their routine that can 
mask or alter the results of this study 
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 Females that remain pregnant during the study 
 Other causes (e.g. pre-existing higher protocol deviation, undetected 
disease on day 0, etc ...) 
 For animals receiving non-authorised treatments, the permanence or 
withdrawal of concomitant treatments in the study was evaluated in each 
case depending on the treatment used, and the time lapsed to the next 
clinical evaluation. As a general rule the guidelines proposed by the 
Fédération Equestre Internaciale (FEI) were used on drugs withdrawal time 
before a competition, since these drugs can have an effect on clinical or 
sports performance of animals. Depending on the date of application of 
concomitant therapy, and analysing treatment case by case, it was 
determined whether the animal should be removed of the trial, or not.  
 Pregnant or lactating mares during the study 
 
5.8. Efficacy Assessment 
5.8.1. Lameness Improvement 
Equine lameness is one of the clinical symptoms with the most consequences in their 
sporting life and in their quality of life. 
Likewise, for the competition, the horses must be free of consistent lameness at trot 
(<1 grade AAEP) in order to participate in international competitions (Fédération 
Equestre Internationale (FEI)). 
For this reason, to evaluate the efficacy of a medication for the equine locomotor 
system, the evaluation of lameness is essential. 
In order to evaluate the effectiveness of the EUC-MSC the reduction of equine 
lameness was elected as endpoint. However in this work we wanted also to confirm 
that the efficacy was sufficient to significantly improve the quality of life and sports 
capacities of horses. 
The primary variable of this study aimed to establish a cut off where the animal did not 
present a clear or consistent limp and that allowed it to develop a normal sporting life 
after the treatment.  
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Also, it is well known that the mechanism of action of MSCs is a complex mechanism 
based on joint immunomodulation, so the time from the administration of the product 
until the animal improves significantly is rather weeks than days. 
For all these reasons the primary endpoint was establishes as: improvement in the 
lameness grade to a non-lame or an inconsistent lameness (≤ grade 1 AAEP scale) 63 
days post treatment. 
Horses that reach the primary endpoint were classified as: Therapeutic Success. 
In addition to the primary variable defined above, we also evaluated: the average 
decrease in lameness at day 63, the decrease or not in lameness at day 63 and the 
therapeutic success at day 14 and 35. All these variables were assessed as secondary 
endpoint. 
5.8.2. Effusion 
Effusion is an indirect measure of the degree of joint involvement and the degree of 
joint inflammation. Horses affected by OA may have increased joint effusion, have it 
normal or have it decreased. 
In the present study all degrees of joint effusion were allowed. 
In order to evaluate the capacity of EUC-MSC in the improvement of joint effusion, the 
effect on this clinical symptom was evaluated as a secondary variable. The response to 
effusion was evaluated as secondary endpoint. 
5.8.3. Flexion Pain 
The pain and increased lameness after active (or passive) flexion test of the affected 
joint is a very frequent sign in equine OA. 
For participation in the present study all horses should show increased pain after 
active flexion. 
Being flexion pain a characteristic sign of OA, it was interesting to know the effect that 
EUC-MSC has on flexion pain in treated horses. The response to flexion pain was 
evaluated as secondary endpoint. 
5.8.4. Overall Improvement 
The overall improvement was defined as the sum of the lameness (punctuated 
according to the AAEP from 0-5), the flexion pain (from 0-3) and the effusion (from 0-
2) summation. The sum of the three variables gives a total of 10 points. The overall 
improvement as defined above was evaluated as secondary endpoint. 
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5.8.5. Subjective improvement 
With the objective to find an added value, the researcher and the owner (or rider) was 
asked upon completion of the Clinical Trial about their opinion in the results of the 
treatments, unbeknownst to them if placebo or IVP was used (blind). 
The subjectively opinion of the degree of improvement of the animals was taking into 
account the following parameters: 
 The improvement, in cold, of the horse immediately outside the box 
 Degree of improvement of the horse during the exercise practice 
 Degree of improvement in sports skills 
 Degree of improvement in pain sensation 
To each animal, both the veterinarian and owner (or rider), assigned a punctuation of 
improvement from 0 to 10, where 0 was no improvement and 10 complete 
improvement. 
 
5.9. Safety Assessment 
For the safety assessment a detailed analysis of all adverse events suffered by the 
participating horses were evaluated. 
On a case-by-case basis, each adverse event was evaluated in order to determine its 
relationship or not with the drug under study and / or the route of administration. 
The safety assessment has been carried out based on the assessment of the severity 
and prevalence of the adverse events occurred. 
 
5.10. Statistical Methodologies 
This study was a superiority comparative, parallel, controlled, multicentric, blinded 
Clinical Trial.  
Statistical analyses were carried out based on the guidance document "Guideline on 
statistical principles for Clinical Trials for veterinary medicinal products 
(pharmaceuticals)" of 16 January 2012 (EMA / CVMP / EWP / 81976/2010). 
Statistical analysis was conducted in the population by protocol (PP) and for 
population to be treated (PTT). 
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Basal Homogeneity: for qualitative explanatory variables the appropriate test for 
comparing treatment groups will be used (Chi-Square test, Fischer’s exact test or LR 
Chi-Square test). For quantitative explanatory variables the appropriate test for 
comparing treatment groups will be used (t-test, Mann-Whitney’s test). 
Qualitative Response Variables (reduction > value): the appropriate test for 
comparing qualitative variables between treatment groups will be used (Chi-Square 
test, Fischer’s exact test or LR Chi-Square test). 
Quantitative Response Variables (Longitudinal Analysis): A linear mixed model will be 
used considering the animal as a random Factor and Time, Treatment and their 
interaction as fixed factors. The compliance of application conditions will be performed 
qualitatively through residuals plots.  Alternatively, methods considering the 
appropriate generalised linear mixed models will be applied  
In order to account for the basal severity of the animals, all analyses use basal 
evaluations as reference values. 
 
5.11. Co-variables 
OA has a multifactorial origin where certain factors could influence both the evolution 
of the disease and the effectiveness of treatments against it. 
According to clinical experience and bibliography, there are some variables that could 
influence in the efficacy outcome of a product. 
In order to elucidate if some equine population could have better or worse response to 
EUC-MSCs than others depending of different variables (age, affected joint, activity 
level…) an efficacy co-variable study was made. 
The effect of many different co-variables was investigated: 
 Lameness grade before treatment 
 Radiological Image 
 Horse weight 
 Sex 
 Age 
 Affected Limb (frontlimb or hindlimb) 
 Life habits (box, semi-liberty or life in meadow) 
 Joint (fetlock, proximal, interphalangeal, etc) 
 Chronicity 
 Activity level 
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The election of the co-variables was based in veterinary parameters: clinical 
experience of the author and bibliographic research, considering that those variables 
could have some kind of influence in the efficacy of the product. 
Based on veterinary parameters and bibliographic references it could be hypothesised 
that: the greater the lameness, the less effective; the greater the radiological signs, the 
less efficacy; the greater the age, the lower the efficacy and the greater the chronicity, 
the less effective. 
On the other hand, no relationship is expected between sex, weight, affected limb, 
joint and activity level on the efficacy outcome, neither in the bibliography nor in the 
clinical experience of the author. 
 
5.12. Comparison with conventional treatments 
In the equine sector, there are different treatments available for equine OA, however 
almost all of them are symptomatic treatments that are incapable of slowing down the 
evolution of the disease and are associated with long-term side effects. 
Of all the treatments available, the use of intra-articular corticoids + hyaluronic acid 
(Cos+HA) can be considered the most commonly used conventional treatment in the 
treatment of equine OA. 
MSCs has being postulated as a therapeutic alternative for the treatment of OA, 
however, to be able to effectively consider them as a realistic alternative, a 
comparison of both products must be carried out objectively. 
The information of conventional treatments has been provided by bibliographyc 
references: Harkins et al., 1993; Van Weeren & de Grauw, 2010; de Grauw et al., 2015; 
Souza, 2016. 
The information of EUC-MSC has been obtained by the present work and the author's 
knowledge. 
For this comparison, different aspects will be taken into account: cost, effectiveness, 
adverse events and indirect cost.  
Both products will be compared by representing them in a radial chart. The chart will 
be divided into 5 radius or sections. The larger area occupied the better result for 
product. 
Cost: The cost have been estimated considering the final price that the owner of the 
horse will pay. The graphic is divided into 5 radius: between 801-1000 €, 601-800 €, 
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401-600€, 201-400 € and 0-200€. Price data has been established asking to different 
veterinarians in Spain. 
Effectiveness: Considering the effect of the product in lameness reduction. For 
evaluate the efficacy of CO+ HA the publication of de Grauw, 2015 was used. The 
efficacy is divided into 5 sections: between 0-20%, 20-40%, 40-60%, 60-80%, 80-100%. 
Adverse Event: Considering the safety of the product in general terms. For evaluate the 
safety/adverse event of COs+HA publications of Harkins et al., 1993, Van Weeren & de 
Grauw, 2010; de Grauw et al., 2015 and Souza, 2016 has been used. To classify safety, 
different adverse effects have been scored according to their frequency and severity as 
follows: 
Temporal- Local adverse effects 
Frequency Description Score 
Rare (<10%) 
Mild local sing such us 





Mild local sing such us 





Joint Flare: acute 
lameness and swelling 
1 
Common (>10%) 
Joint Flare: acute 
lameness and swelling 
2 
 
Temporal or Permanent Systemic events adverse effects 
Frequency Description Score 
Very Rare (<1%) 
Sings of systemic illness 






Sings of systemic illness 
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Permanent Local adverse effects 
Description Score 
Negatively affect the 
cartilage homeostasis 
and biosynthetic after 




The safety is divided into 5 sections: ≥9 points, 7-8 points, 5-6 points, 3-4 points and ≤2 
points. 
Indirect Cost: : For the analysis of indirect costs, it has been taken into account: the 
days of sports loss by dopping, the days for sports loss from the application of the 
product until its effectiveness and duration of the clinical effect. For evaluate the 
indirect cost of COs+HA publications of Harkins et al., 1993, de Grauw et al., 2015  and 
Souza, 2016 has been used. 
To classified indirect cost the following points have been scored: 
Description Point 





Lose of sport days until 




Duration of the effect ≤ 
1 month 
4 
Duration of the effect 1-
3 months 
3 
Duration of the effect 3-
6 months 
2 
Duration of the effect 6-
12 months 
1 




The indirect cost is divided into 5 sections: ≥5 points, 4 points, 3 points, 2 points and ≤1 
points. 
When both products have been scored according to the guidelines describe bellow, 
both products will be represented in a radius chart. The product with more area will be 
considered better than the other. 
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5.13. Long Term Follow up 
With the intention of knowing the long-term effect of EUC-MSCs, efficacy and safety 
data were collected 2 years post product administration.  
It is important to note that this study of long term follow-up was not done according to 
Good Clinical Practice. Possible adverse effects, concomitant treatments, deviations 
etc. were not recorded following the VICH GL9 regulations. On the other hand, both 
investigator and owner of the animal were not blind in this follow-up period. 
Veterinarians were asked two years after product administration about the moment of 
relapse and about the occurrence of adverse event during the period.
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6. RESULTS 
6.1. Study Design 
The study was designed and conducted according EU guidelines and regulatory 
requirements. The study was conducted in Spain from November 2014 to September 
2017 with two separate enrolment periods. 
In this study there were three well-defined figures: 
Researcher: in this trial the researcher was the clinical vet. Veterinarians were in 
charge of: animal selection, product administration, efficacy and safety reviews, 
adverse event registration, etc. More than 20 different veterinarians from all parts of 
Spain (Table 7) with an average of 20 years of equine practice experience participated 
in the clinical trial as researchers. Each horse was always evaluated by the same 
veterinary in order to avoid inter-observer variability. 
Clinical Trial Monitor: An individual responsible of overseeing a clinical study and 
ensuring that it is conducted, recorded and reported in accordance with the study 
protocol and good clinical practice. The tasks of the monitor were to ensure 
compliance with the protocol, provide support and training to veterinarians regarding 
the clinical trial, review the data collection notebooks, as well as any aspect related to 
the execution of the trial (days of visits, concomitant treatments, adverse effects, etc.). 
Sponsor:  An individual, company, institution or organization which takes responsibility 
for the initiation, management and financing of a clinical study for the veterinary 




W.M Vet Graduated 1972. Equine Specialist Practitioner since 1973. Madrid 
G.C Vet Graduated 2004. Equine Specialist Practitioner since 2005 Alicante 
M.P Vet Graduated 1990. Equine Specialist Practitioner since 1992 Valladolid 
J.A Vet Graduated 2003. Equine Specialist Practitioner since 2003 Ciudad Real 
F.G Vet Graduated 1995. Equine Specialist Practitioner since 1998 Madrid 
D.J Vet Graduated 2009. Equine Specialist Practitioner since 2009 Madrid 
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F.R Vet Graduated 1988. Equine Specialist Practitioner since 1992 
Cantabria/ 
Asturias 
J.G Vet Graduated 1990. Equine Specialist Practitioner since 1992 Cataluña 
P.S Vet Graduated 1992. Equine Specialist Practitioner since 1995 Cataluña 
G.G Vet Graduated 1991. Equine Specialist Practitioner since 1995 Cataluña 
I.M Vet Graduated 2008. Equine Specialist Practitioner since 2008 Madrid 
M. V Vet Graduated 1992. Equine Specialist Practitioner since 1995 Asturias 
I. G Vet Graduated 1990. Equine Specialist Practitioner since 1993 Valladolid 
J.V Vet Graduated 1997. Equine Specialist Practitioner since 2000 Andalucía 
JM. R Vet Graduated 2011. Equine Specialist Practitioner since 2012 Andalucía 
JM. M Vet Graduated 2000. Equine Specialist Practitioner since 2001 Madrid 
J. R. Vet Graduated 1998. Equine Specialist Practitioner since 1999 Andalucía 
V. O. Vet Graduated 1990. Equine Specialist Practitioner since 1991 Valencia 
H. R Vet Graduated 2007. Equine Specialist Practitioner since 2007 Barcelona 
M.V Vet Graduated 2000. Equine Specialist Practitioner since 2001 Gerona 
P.A Vet Graduated 1988. Equine Specialist Practitioner since 1990 Madrid 
S.G Vet Graduated 2011. Equine Specialist Practitioner since 2012 Valencia 
R. H Vet Graduated 1987. Equine Specialist Practitioner since 1987 Madrid 
Table 7: Researchers credentials 
The study has a fixed visit schedule that was met by all the vets and horses with the 
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6.2. Enrolled Animal and withdrawals  
In the present study a total of 76 horses were enrolled (36 received treatment and 40 
placebo). 
A total of seven horses were withdrawn before completion the clinical trial due the 
following reasons: 
Lack of adherence to the protocol: 
It had been impossible for the monitor to make the proper monitoring of the animal. 
The investigator did not answer the requests on the monitoring plan established. The 
monitor was unable to maintain a fluid communication with the investigator that 
allows the monitor to know the appearance of adverse events or concomitant therapy. 
It had been impossible to recover the Data Collection Notebook. Therefore, this horse 
had not been included in the data analysis.  
Changes in the sport and life habits: 
During the clinical trial, as reflected in the protocol of study all the horses must have 
the same activity and life habits during the clinical trial and at least 4 weeks before the 
stating of the trial, in order to prevent possible bias of the results. For example, if a 
horse reduces or increases the activity level during the evaluation period, the animal 
was withdrawn. 
Four horses suffered changes in their routine habits and/or changes in the activity level 
during the trial (or 4 weeks previous the enrolment). The changes suffered were: 
climatological reasons that meant that 2 horses were not able to perform normal 
activity level during 15 days (from day -15 to day 0); horse owner was not able to ride 
the horse as it was used to (2 horses from day -15 to day 0 in one horse and from day 0 
to day 14 in other horse). 
Non-related adverse event: 
One horse was withdrawn because due to the trial suffering a non-related adverse 
event. The horse suffered a Superficial Flexor Tendon (SDFT) injury that requires a 
change in the habits (rehabilitation plan) and change in the shoeing, as an anti-
inflammatory treatment. 
According to the protocol of the study, in the case an AE is detected all the possible 
measures would be taken in order to discover the origin of the AE. In order to diagnose 
the horse an ultrasound was made and an image compatible with Superficial Flexor 
Tendon injury was observed. 
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Horse sold outside Spain: 
After product administration (day 45) one horse was sold outside of Spain. It was 
impossible for the researcher to perform the last revision visit and therefore the horse 
was withdrawn.  
The horse was not included in the statistical data at any time-point since the data 
collection notebook was not available. 
 
6.3. Basal Homogeneity 
Breed 
Any breed was accepted. Pure race horses as Arabian, Spanish Pure Race (PRE) and 
sport horses (Spanish sport horse, Westfalian, sille francais, etc) but also crossbreed 
horses were enrolled. The different breeds in the trial are represented bellow: 
 
Figure 18: Breed enrolled in the clinical trial 
Age 
Mature horses were eligible for the study. The main age in the clinical trial was 11.8 
years. The homogeneity in term of age within the groups has been demonstrated as 
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Total 69 0 72.7 18.0 70.9 216 4 55.6 89.7 
Placebo 37 0 70.4 18.0 71.2 216 4 46.6 94.1 
Treatment 32 0 75.3 34.5 71.7 204 5 49.5 101.2 
 
 P-Value  
Kruskal-Wallis Test 0.7678  
Table 8: Basal Homogeneity- Age 
Sex 
Female, Male and castrated male were accepted (pregnant mares were excluded). The 




N % N % 
Male 4 11.1% 2 6.3% 
Castrated Male 24 63.9% 19 59.4% 
Female 9 25.0% 11 34.4% 
TOTAL 37 100.0% 32 100.0% 
 
 P-Value  
LR - Chi-Square Test 0.5987  
Table 9: Basal Homogeneity- Sex 
 
Weight 
The main body weight during the trial was 465 kg. The homogeneity in terms of body 
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Total 68 1 464.7 450.0 66.8 650 300 448.5 480.9 
Placebo 37 0 455.9 450.0 76.3 650 300 430.5 481.3 
Treatment 32 1 475.2 480.0 52.7 600 400 455.9 494.5 
 
 P-Value  
Kruskal-Wallis Test 0.1521  
Table 10: Basal Homogeneity- weight 
Life Habits 
All kind of life habits were accepted in the study, from horses that live in complete 
freedom in a meadow to horses that live in a box. 




N % N % 
Box 16 43.2% 12 37.5% 
Meadow 6 16.2% 4 12.5% 
Semi-Liberty 15 40.5% 16 50.0% 
TOTAL 37 100.0% 32 100.0% 
 
 P-Value  
Chi-Square Test 0.7244  
Table 11: Basal Homogeneity- Life Habits 
 
Horse use 
Different types of horses were accepted from high level sport horses to leisure horses. 
Approximate half of the horses were dedicated to sport activities and the other half 
were leisure horses. 
The types of horses used are detailed in the following figure: 
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Figure 19: Used of the enrolled horses in the clinical trial 
 
The homogeneity within groups in terms of use of the enrolled horses has been 
investigated and demonstrated: 
 
PRINCIPAL ACTIVITY IN 
THE LAST 12 MONTHS 
TX 
Placebo Treatment 
N % N % 
Jump 7 18.9% 5 16.7% 
Dressage 7 18.9% 8 26.7% 
Leisure 14 37.8% 11 36.7% 
Equestrian Lessons 9 24.3% 6 20.0% 
TOTAL 37 100.0% 30 100.0% 
 
 P-Value  
Chi-Square Test 0.8882  
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Activity level of horses during the clinical trial: 
During the present clinical trial all kind of activity level were allowed. The activity level 
has been defined as: low (box rest or hand walk), moderate (ridden occasionally 2 days 
per week), high (ridden at all gaits often), very high (sport competitions or hard work). 
The activity level of the horses during the clinical trial is described in the following 
figure: 
 
Figure 20 : Activity level of horses during the clinical trial 
 
Both groups were homogenous with respect to the activity level during the present 




N % N % 
Low 11 29.7% 14 43.7% 
Medium 13 35.1% 7 21.9% 
High 9 24.3% 5 15.6% 
Very high 4 10.8% 6 18.8% 
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 P-Value  
LR - Chi-Square Test 0.3580  
Table 13: Basal Homogeneity- Activity Level 
 
6.4. Diagnosis 
The diagnosis was made as previously described without deviations. During the 
diagnosis some horses were not enrolled in the study due to different reasons such as: 
severe OA, presence of joint chips, no clear response to the intra-articular block, etc. 
The radiological degree (According Cornelissen Radiographic Scale adapted to all 
joints) of the enrolled horses is described in the table below: 
Radiological degree Treatment Placebo 
Grade 1 9 7 
Grade 2 13 16 
Grade 3 10 14 
Table 14: Radiological degree according Cornelissen Radiological Scale 
 
The homogeneity within the groups in the radiological degree has been demonstrated 




N % N % 
1 7 18.9% 9 28.1% 
2 16 43.2% 13 40.6% 
3 14 37.8% 10 31.3% 
TOTAL 37 100.0% 32 100.0% 
 
 P-Value  
LR - Chi-Square Test 0.5545  
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With respect to the enrolled joints, several joints were enrolled, though mainly 
interphalangeal joints were included. The list of the enrolment joints and its 
distribution within groups is detailed in the table below: 
Joint Treatment Placebo 
Distal interphalangeal 14 12 
Proximal interphalangeal 3 12 
Metacarpal-phalangeal 8 11 
Radiocarpal  1 0 
Tarsal 6 1 
Stifle 0 1 
Table 16: Joint distribution 
 
Interestingly, the joint distribution was not homogeneous within groups (p=0.0426). 
The impact of the joint in the treatment effectiveness will be evaluated further. 
 P-Value  
LR - Chi-Square Test 0.0426 * 
Table 17: P-value joint distribution 
 
Considering the lameness evaluation, groups were also balanced before treatment 




N % N % 
1 5 13.5% 2 6.3% 
1.5 2 5.4% 1 3.1% 
2 17 45.9% 16 50.0% 
2.5 4 10.8% 3 9.4% 
3 9 24.3% 10 31.3% 
TOTAL 37 100.0% 32 100.0% 
 
 P-Value  
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Total 69 0 2.2 2.0 0.6 3 1 2.1 2.4 
Placebo 37 0 2.1 2.0 0.6 3 1 1.9 2.3 
Treatment 32 0 2.3 2.0 0.6 3 1 2.1 2.5 
 
 P-Value  
Kruskal-Wallis Test 0.3659  
 
Table 18: Basal Homogeneity- Lameness degree 
 






N % N % 
0 13 35.1% 13 40.6% 
1 18 48.6% 14 43.8% 
1.5 1 2.7% 1 3.1% 
2 5 13.5% 4 12.5% 
TOTAL 37 100.0% 32 100.0% 
 
 P-Value  
LR - Chi-Square Test 0.9691  
 





Total 69 0 0.8 1.0 0.7 2 0 0.6 0.9 
Placebo 37 0 0.8 1.0 0.7 2 0 0.6 1.0 
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 P-Value  
Kruskal-Wallis Test 0.6945  
Table 19: Basal Homogeneity-joint effusion 
 




N % N % 
1 7 18.9% 6 18.8% 
1.5 1 2.7% 0. . 
2 18 48.6% 18 56.3% 
2.5 2 5.4% 0. . 
3 9 24.3% 8 25.0% 
TOTAL 37 100.0% 32 100.0% 
 
 P-Value  
LR - Chi-Square Test 0.4153  
 





Total 69 0 2.1 2.0 0.7 3 1 1.9 2.2 
Placebo 37 0 2.1 2.0 0.7 3 1 1.8 2.3 
Treatment 32 0 2.1 2.0 0.7 3 1 1.8 2.3 
 
 P-Value  
Kruskal-Wallis Test 0.9476  
Table 20: Basal Homogeneity- Flexion Pain 
 
In addition, the basal homogeneity in terms of the chronicity of the symptoms 
(expressed in months) has been evaluated, and both groups were comparable: 
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Total 69 0 7.5 4.0 7.9 30 1 5.6 9.4 
Placebo 37 0 6.6 4.0 6.5 30 1 4.4 8.7 
Treatment 32 0 8.5 4.0 9.2 30 1 5.2 11.8 
  
 P-Value  
Kruskal-Wallis Test 0.6232  
Table 21: Basal Homogeneity- Chronicity 
 
6.5. Efficacy Assessment 
6.5.1. Lameness 
This study has been designed to demonstrate the efficacy of the intra-articular 
administration of 15 million Equine Umbilical Cord Mesenchymal Stem Cells (EUC-
MSCs) in the treatment of symptoms associated in mild to moderate osteoarthritis in 
horses under field conditions. 
Due to the importance of Lameness grade in the ability of horses to develop normal 
life, the lameness improvement 63 days after product administration has been 
established as primary endpoint. 
In the treatment group 84.4% of the horses presented some kind of improvement in 
the lameness grade compared with 48.6% in the placebo group, being this difference 
statistically significant (p=0.0019 Chi-Square Test). 
However, the objective of this study was not only to demonstrate the improvement in 
the lameness grade of horses treated with EUC-MSCs, on the other hand, the objective 
of the present research was to investigate if EUC-MSCs were able to produce an 
improvement in the lameness grade that was substantial enough to allow the horses 
to perform normal life or sport abilities. 
In this respect the primary designed endpoint was a more restricted endpoint, in order 
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Primary endpoint:  
The primary efficacy endpoint was based in the comparison of the percentage of 
animals classified as Therapeutic Successes at day 63 (± 2) in the treatment group 
versus the control group inoculated with placebo. 
The percentage of animals in the treatment group vs. placebo with an improvement in 
the lameness grade to a non-lame or an inconsistent lameness (≤ grade 1 AAEP scale) 
63 days post treatment was compared. 
Represented below are the overall results (in percentage) separated by groups 






N % N % 
No 29 78.4% 9 28.1% 
Yes 8 21.6% 23 71.9% 
TOTAL 37 100.0% 32 100.0% 
 
 P-Value  
Chi-Square Test <.0001 * 
 
Table 22: Percentage of therapeutic success by groups at da 63 
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Figure 21: Primary endpoint 
Secondary endpoints: 
In addition, the same endpoint (improvement in the lameness grade to a non-lame or 
an inconsistent lameness (≤ grade 1 AAEP scale)) was investigated at day 35 and 14 
post treatment. 
At day 35 post treatment the efficacy of the treatment group was statistically 
significantly superior compared to the placebo group (p=0.0066). However, at day 14 






N % N % 
No 29 78.4% 15 46.9% 
Yes 8 21.6% 17 53.1% 
TOTAL 37 100.0% 32 100.0% 
 
 P-Value  
Chi-Square Test 0.0066 * 









































N % N % 
No 29 78.4% 21 65.6% 
Yes 8 21.6% 11 34.4% 
TOTAL 37 100.0% 32 100.0% 
 
 P-Value  
Chi-Square Test 0.2369  
Table 24: Percentage of therapeutic success by groups at day 14 
 
In terms of main improvement of the lameness grade, the treatment group had more 
than 2-fold lameness improvement (according to AAEP lameness scale) compared to a 
main improvement of the placebo group (1.78 points vs 0.88 points) being this 
difference statistically significant (p<0.0001).  
 
Figure 22 : Lameness longitudinal Analysis (T0 represents placebo horses; T1 represents treatment horses)  
Difference vs ControlDifference vs D0
Visit Day
T1T0
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Simple Effect Comparisons of t*TX Least Squares Means By t 
Simple 
Effect 
Level TX _TX Estimate 
Standard 
Error DF t Value Pr > |t| 
t 0 T0 T1 -0.03084 0.1656 207 -0.19 0.8524 
t 14 T0 T1 0.2124 0.1656 207 1.28 0.2010 
t 35 T0 T1 0.6136 0.1663 207 3.69 0.0003 
t 63 T0 T1 0.8940 0.1656 207 5.40 <.0001 
Table 25: Logitudinal Lameness statistical significance 
 
6.5.2. Effusion 
Here, the average improvement in swelling or effusion in the treatment group, 
compared with the improvement average in the placebo group was measured. 
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The mean improvement in the effusion or swelling degree in the treatment group was 
0.34 points and the main improvement in the placebo group was 0.16 points. Despite 
having double improvement in effusion degree in the treatment group compared to 
placebo group, no statistically significant differences were found at any time points 
between groups. 
Simple Effect Comparisons of t*TX Least Squares Means By t 
Simple 
Effect 
Level TX _TX Estimate 
Standard 
Error DF t Value Pr > |t| 
t 0 T0 T1 -0.1509 0.09913 207 -1.52 0.1295 
t 14 T0 T1 -0.1256 0.09913 207 -1.27 0.2067 
t 35 T0 T1 -0.08098 0.09944 207 -0.81 0.4164 
t 63 T0 T1 0.03069 0.09913 207 0.31 0.7572 
Table 26: Swelling statistical significance 
6.5.3. Flexion pain 
At this point, the average improvement in flexion pain in the treatment group, 
compared with the average improve in the placebo group was measured. 
 
Figure 24: Flexion Pain longitudinal Analysis (T0 represents placebo horses; T1 represents treatment horses) 
RESULTS 
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Differences were observed between the two groups in reference to the flexion pain at 
day 63 (±2) with a Statistical significance of p< 0.0001. Statistical significance p= 0.0012 
was also observed at day 35(±2), and at day 14(±2) (p=0.0224). 
Simple Effect Comparisons of t*TX Least Squares Means By t 
Simple 
Effect 
Level TX _TX Estimate 
Standard 
Error DF t Value Pr > |t| 
t 0 T0 T1 0.2244 0.1775 207 1.26 0.2077 
t 14 T0 T1 0.4085 0.1775 207 2.30 0.0224 
t 35 T0 T1 0.5868 0.1784 207 3.29 0.0012 
t 63 T0 T1 0.8409 0.1775 207 4.74 <.0001 
Table 27: Flexion Pain statistical significance 
 
6.5.4. Overall improvement 
As seen in previous points, lameness and flexion pain were significantly reduced in all 
study time points compared with placebo, although this effect was not observed in 
joint effusion. 
It can be seen that the overall score reduction in the summation of lameness + effusion 
+ flexion pain was 2.8 points in the treatment group compared to 1 point in the 
placebo group, being this difference statistically significant. 
RESULTS 
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Figure 25: Total Score longitudinal Analysis (T0 represents placebo horses; T1 represents treatment horses) 
 
Simple Effect Comparisons of t*TX Least Squares Means By t 
Simple 
Effect 
Level TX _TX Estimate 
Standard 
Error DF t Value Pr > |t| 
t 0 T0 T1 0.1209 0.3340 207 0.36 0.7176 
t 14 T0 T1 0.5736 0.3340 207 1.72 0.0873 
t 35 T0 T1 1.1973 0.3355 207 3.57 0.0004 
t 63 T0 T1 1.8439 0.3340 207 5.52 <.0001 
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6.5.5. Subjective improvement opinion 
Owners (rides) and veterinarians were asked about the subjective improvement of the 
animal 63 days after product administration. The improvement was scored from 0 to 
10, being 0 no improvement and 10 complete improvement 
The average results obtained (expressed in percentage) in both groups are shown 
below:  
 
Figure 26: Subjective improvement by owner and vet 
As shown in the graph, the improvement in the treatment group was more than 2-fold 
than in the placebo group. 
6.6. Co-variables study 
The potentially influence of co-variables or epidemiologic circumstances in the horses 
has been evaluated in order to elucidate if the efficacy of EUC-MSC could be 
dependent on certain epidemiological factors. 
To assess the impact of the co-variables, the efficacy (defined as lameness reduction to 
non-lame or inconsistent lameness-primary endpoint) of each co-variable has been 
evaluated and a statistical analysis has been performed. 
Multiple co-variables have been analysed (Table 29) showing that none of the 
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DF F Value Pr > F 
Lameness 1 48 2.63 0.1113 
RX image 1 48 3.37 0.0728 
Weight 1 48 2.79 0.1012 
Sex 2 48 1.00 0.3756 
Age 1 48 0.38 0.5431 
Limb 1 48 1.71 0.1972 
Life Habits 2 48 1.08 0.3466 
Joint 3 48 0.81 0.4944 
Chronicity 1 48 0.00 0.9746 
Activity level 1 48 0.04 0.8388 
Table 29: Gross co-variable study 
 
Those variables that according to the bibliography or clinical criteria may have more 
influence on efficacy have been evaluated in more detail 
Lameness grade: the influence of the lameness grade previous to product 
administration has been evaluated in the efficacy outcome. It could be expected that 
the greater the degree of lameness, the less effective the product, however, as seen in 
the table below the efficacy of EUC-MSC was comparable regardless of the lameness of 
the horse prior to administration. 
Efficacy dependant on lameness grade before product administration 
Lameness grade ≤2 before product administration 78% 
Lameness grade ≤3 before product administration 66% 
Table 30: Lameness grade and efficacy 
 
Radiologic degree: the influence of the radiologic degree in the efficacy outcome has 
been evaluated. It could be expected that the higher the degree of radiological signs, 
the less effective the product, but as can be seen in the table 30, the efficacy rate of 
MSCs seems to be reduced as the radiological signs increase, however these 
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Efficacy dependant on radiologic degree before product administration 
Rx grade <1 100% 
Rx grade ≤2 76% 
Rx grade ≤3 60% 
Table 31: Radiological Degree and efficacy 
 
Age: the effect that age could have in the efficacy of EUC-MSC is described in the table 
below. It might be expected that the older the horse is, the lower efficacy of the 
product. As seen the efficacy of EUC-MSC is very similar in young horses (<10 years) 
than in mature horses (>10 years). (Table 32) 
Efficacy dependant on horse´s age 
≤10 years 70% 
>10 years 67.5% 
Table 32: Age and efficacy 
 
Chronicity: it could be expected that the more chronic the symptoms are the poor 
prognostic the treatment has. However as seen bellow the efficacy of EUC-MSC is even 
better in horses with more than 3 months of symptoms evolution. 
Efficacy dependant on horse´s chronicity 
≤3 months 80% 
>3 months 60% 
Table 33: Chronicity and efficacy 
 
Activity level: the impact of the activity level of the horse after product administration 
has been evaluated since could be expected that horses with high activity level could 
have worse efficacy after treatment administration. However, in light of the results, 
the exercise after treatment does not negatively affect to the efficacy. However, it is 
important to keep in mind that, in the present study, each horse adapted its level of 
sport activity based on its clinical condition, so it is possible that horses with less sports 
activity also had a greater clinical symptomatology.  




Very high 100% 
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6.7. Comparison of conventional treatments 
A comparative assay between conventional treatments Costicosteroids + Hyaluronic 
Acid (COs+ HA) and EUC-MSC has been done. The information of conventional 
treatments has been provided by bibliographic references. The information of EUC-
MSC has been obtained by the present work and the author's knowledge. 
Cost: Considering the high manufacture price of Advance Therapies, the cost of this 
kind of medicines for the final owner is about 800€, on the other hand, conventional 
treatments (CO+HA) are quite cheap products with an estimate cost around 200€. 
Therefore EUC-MSCs receives a score of 2 and CO + HA a score of 5 in the radius graph. 
Effectiveness: Considering the effect of the product in lameness reduction. For 
evaluate the efficacy of CO+ HA the publication of de Grauw, 2015 was used. In this 
work de Grauw evaluated the intraarticular efficacy of CO+HA in 39 horses. The 
efficacy in lameness reduction 3 weeks after CO+HA injection was 64%. As seen above 
the efficacy of EUC-MSC is 72%. The efficacy of both products is between 60-80% 
therefore 4 points in the graph were assigned for both products. 
Adverse Event: Considering the safety of the product in general terms. Temporal- Local 
adverse effects describe in COs are: 2% risk of joint flare (Harkins & Tobin, 1993) and 
˜3% of mild local swelling (de Grauw et al., 2014), on the other hand the risk of joint 
flare in EUC-MSC is 11% and the incidence of local swelling ~8% (see point 5.11 
Adverse Events). In addition the use of COs have been associated with systemic 
adverse event such us laminitis, adrenal insufficiency, hyperadrenocorticism, despite 
the incidence of this kind of systemic adverse event is very low could not be ignored. 
Moreover, the use of COs has been related with severe deleterious effect in the 
cartilage homeostasis that potentially accelerates joint degradation or even leading to 
a devastating disease known as Steroid Arthropathy ((Harkins & Tobin, 1993). Although 
the negative effects of corticosteroids, they are usually associated with repeated 
administrations or high doses (Van Weeren & de Grauw, 2010) considering that OA is a 
chronic disease and that the therapeutic action of corticosteroids is limited, repeated 
use of corticosteroids is practically inevitable. 
Therefore, with respect to adverse event, the total score of EUC-MSCs is 3 points (1 
point rare mild effusion + 2 points common joint flare) while the total score of COs + A 
is 7 (1 point rare mild effusion + 1 point rare joint flare + 2 points very rare systemic 
adverse event + 3 points deleterious cartilage effect in repeated or high doses). These 
scores are transferred to the graph by assigning a punctuation of 4 to EUC-MSC and 2 
to CO + HA. 
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Indirect Cost: For the analysis of indirect costs, it has been taken into account: the days 
of sports loss by doping, the days for sports loss from the application of the product to 
its effectiveness and relapses from the disease. For evaluate the indirect cost of 
COs+HA, publications of Harkins et al., 1993, de Grauw et al., 2015  and Souza, 2016 
have been used. 
COs+HA have lost of sport days due doping that depending on the product could be 15 
days; on the other hand, as seen before, the time until efficacy of EUC-MSC is about 30 
days; therefore both products are considered to lose useful days until the horses can 
enter into competition, either by doping or by time until the product is effective. 
An important point to assess in the calculation of the indirect cost is the duration 
effect of the product. It is considered the less duration effect of a product, the more 
indirect cost associated, since when the horses relapse, the horse needs to be 
removed from the competition, the veterinarian must be called and treated horse 
again and a new doping period begins. 
The duration of corticosteroids depends on the type of corticosteroid used, the type of 
injury, the times corticosteroids have been administered before, etc. The most used 
COs in the equine clinic is triamcinolone with a medium duration (Van Weeren & de 
Grauw, 2010). In de Grauw (2014) study it was seen that 3 months after treatment 
with COs+HA less than 50% of the horses were working at previous level. On the other 
hand the efficacy of EUC-MSC is long term, with more than 70% of the treated horses 
without relapse 12 months after treatment.  
Has been considered that CO+HA have indirect cost due doping period and medium 
effect duration (2 points score in the radius graph), on the other hand EUC-MSCs have 
lost of working days due the time until efficacy, but have long-term efficacy, so a score 
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Therefore, by representing both products in a radius chart (Figure 27), the product that 
occupies more area is considered better. 
 
Figure 27: Comparative between EUC-MSCs and COs+HA 
 
Graphically, it can be seen that EUC-MSC is a competitive treatment compared to 
conventional treatments, despite having a sale price substantially higher than COs + 
HA, its high safety profile and its lower indirect cost thanks to its long therapeutic 
effect, generates that EUC-MSCs are not only a real alternative to conventional 
treatments but also EUC-MSC have fundamental advantages for the equine sector, 
especially in sports animals. 
 
6.8. Physical Examination 
Horses were reviewed daily by the stud staff for general health condition and as per 
protocol on day -15 to -7, day 0, 1, 14(±2), 35(±2) and 63(±2) by the researcher. 
The physical exam included: Attitude, corporal condition, hydration, mucous, denture, 
lymph nodes, respiratory auscultation, nasal discharge, pulse, quality pulse, cardiac 
auscultation, peristalsis, injection point and digital pulse. 
The physical exam only detected a couple of minor alterations limited to digital pulse 
(detected in 7 horses), or mild distension (detected in 3 horses) all them related to 
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Eventually non-related product alterations were detected, such as eye discharge (1 
horse), Auricular Block Grade II (1 horse) or alterations in the denture (three horses). 
6.9. Laboratory Examinations 
No clinically relevant data was obtained in the laboratory examinations.  
Minor findings detected were previous to the product administration and considered 
without pathological relevance. 
 
6.10. Safety Assessment  
Horses were reviewed daily by the stud staff for general health condition as per 
protocol on day -15 to -7, day 0,1, 14(±2), 35(±2) and 63(±2) by the researcher. 
According to Good Clinical Practices, adverse events are defined as any “untoward 
medical occurrence” in a patient who receives a drug while participating in 
a clinical study with or without relation to the study product. 
Adverse events (AE) observed in each treatment group during the study have been 
listed, and their incidences were compared. The relationships between AE and 
treatment have been classified in probable, possible, and unlikely by the researcher. 
Probable: 
 Joint Flare: 
EUC-MSCs treatments have been related to acute inflammation 24h after its 
application (Ferris et al., 2013). This described adverse reaction is usually called joint 
flare, the incidence, description, and resolution of this adverse event is detailed in the 
table below. 
Incidence Appearance Description AE-drug relation AE resolution 
4 horses from 36 
treated (11%) 
The AE appeared 
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Following the World Health Organization criteria a rate classified as "Very Common" 
with a frequency ≥ 1/10 incidence. Therefore, the incidence of this adverse event has 
been classified as: very common. 
 
 Local inflammation without lameness associated: 
Local inflammations as joint swelling or effusion, and/or mild local oedema but 
without an acute increase of lameness associated were reported. The incidence, 
description and resolution of this adverse event are detailed in the table below. 
Incidence Appearance Description AE-drug relation AE resolution 
3 horses from 36 
treated (8.3%) 
The AE appeared 















Table 36: Mild inflammation adverse event 
Following the World Health Organization criteria, a rate classified as "Very Common" 
with a frequency ≥ 1/10 incidence. Therefore, the incidence of this adverse event has 
been classified as: very common 
Unlikely related: 
During this clinical trial, some adverse events occurred without treatment product 
relation. These unrelated adverse events are detailed bellow: 
Incidence Appearance Description AE-drug relation AE resolution 
1 horse from 36 
treated (2.7%) 
The AE appeared 
after 14 days of 
treatment 
application 
Surface wound in 
both hindlimbs 




1 horse from 36 
treated (2.7%) 
The AE appeared 
after 14 days of 
treatment 
application 
Mild lung mucus Unlikely 
Complete 
resolution 
1 horse from 36 
treated (2.7%) 
The AE appeared 
after 14 days of 
treatment 
application 






1 horse from 36 
treated (2.7%) 
The AE appeared 
after 25 days of 
treatment 
application 
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Incidence Appearance Description AE-drug relation AE resolution 
1 horse from 36 
treated (2.7%) 
The AE appeared 
after 19 days of 
treatment 
application 
Mild Lameness in 




Table 37: unlike related adverse event 
6.11. Long Term Follow up 
A follow up 2 years after product administration was made in order to know the 
efficacy of the long-term of the product and evaluate the occurrence of adverse effects 
not detected in the initial evaluation period. Data from some horses were lost during 
the 2 years follow up. 
The following results were found: 
Safety: No horse recorded any adverse events related to the product during the follow-
up time. Special attention was paid to the possibility of tumour occurrence, although 
stem cells manufactured according Good Manufacturing Practice have demonstrated 
their wide assurance in regards to tumour formation (European Veterinary Guideline: 
Questions and answers on allogenic mesenchymal stem cell-based products for 
veterinary use: specific questions on tumorigenicity) the relationship of tumours and 
MSC is an unfairly frequently performed association. After this study, it can be 
confirmed that there is no relationship between the administration of EUC-MSCs and 
the formation of tumours in horses. 
Efficacy: The incidence of relapse in the clinical sings (lameness) and the need of re-
treating have been evaluated. Veterinarians were asked when the horse needs to be 
re-treated due relapse in the lameness (Table 38). As can be observed only ~16% of the 
animals were re-treated before 12 months after EUC-MSC treatment, in addition more 
than 40% of the animals still working at normal level 2 years after product 
administration. 
 










8.3% 8.3% 29.2% 42% 12% 




























  Page 96 of 114 
7. DISCUSSION 
Equine OA is a chronic and devastating disease for equine sports medicine that 
presents itself with local inflammation, pain, lameness and loss of joint congruence.  
In this study all horses enrolled presented the typical clinical signs of OA as: lameness, 
flexion pain and joint effusion. 
It is a double-blind design, common in the design of studies for scientific and 
regulatory purposes (Denoix et al., 2003; Lynn et al., 2004; Back et al., 2009; Gough et 
al., 2010 and Koene et al., 2010) that allowed to evaluate the efficacy of the product 
by clinical veterinarians in an impartial and objective manner. 
Regarding the multicentric design, the equine bibliography highlights two types of 
multicentric designs: multicentric with two or three reference centres where the 
veterinarians derive their cases (Denoix et al., 2003; Back et al., 2009 and Koene et al., 
2010) or studies where multiple researchers are recruited throughout the country's 
geography and follow the protocol of the study without deriving the animals to a 
reference hospital (Lynn et al., 2004 and Gough et al., 2010). 
For the present design, the methodology study was chosen with multiple researchers 
for two reasons: 
1) It was considered that the inclusion of many researchers better represented the 
conditions of field use, the final objective that every clinical study should have, by 
increasing the variability of enrolled animals. 
2) Allowed a greater visibility of the study and availability for enrolment. 
With respect to the duration of the study, when designing a clinical study, it is essential 
to know the mechanism of action (MoA) of the product. As earlier described, the MoA 
of the MSCs is through a complex paracrine mechanism mediated mainly by the 
secretion of cytokines (PGE2) that exert an anti-inflammatory and immunomodulatory 
function in the joint. 
This complex MoA causes the therapeutic effect of MSCs to be attained after a few 
weeks after administration, as previously reported by other research groups. Broeckx 
et al., (2013) reported that the improvement after the application of MSCs in horses 
with naturally occurred OA is time dependant, increasing the improvement over the 
weeks. The delayed effect after the use of MSCs was also reported by other authors 
like Saulnier et al., (2014) and Mokbel et al., (2011) where improvement in the animals 
treated with MSCs increased from two months post-treatment. 
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Considering the bibliography, the primary efficacy endpoint was established 2 months 
after treatment administration. In line with the literature, the effectiveness of EUC-
MSCs has been progressive over time, on day 14 post-administration the efficacy rate 
was placed in the 34% while two months after the administration, the efficacy was 
75%. 
Another of the fundamental points of the design of this study (and in general of any 
study) is the establishment of the primary efficacy endpoint. 
The primary endpoint was selected because an improvement to a non-lame or 
inconsistent lameness (1 point or less according to the AAEP scale) represents a 
clinically relevant improvement that allows a horse to re-enter normal training and 
sport life. In addition, this is the criteria of the Fédération Equestre Internationale (FEI) 
for participating in international competitions. (FEI 2018 Veterinary Regulations) 
In many other equine OA-studies, a parameter of 1 grade reduction in lameness (AAEP 
scale) has been defined as therapeutic success (Koene et al., 2010). This means that a 
horse would be classified as therapeutic success if its lameness grade was reduced 
from 3 points to 2 points. Despite one point lameness grade reduction was occurred 
the horse still present a consistent lameness grade that prevents the horse to perform 
normal working. 
Therefore the primary efficacy endpoint in this trial was a more restrictive and 
clinically relevant endpoint, and it was selected to ensure that horses had a real 
improvement that allows them to recover normal life, not only a partial improvement. 
A total of 76 horses were enrolled from different breeds, life habits and horse use. 
Considering that veterinarians from all parts of Spain (central, north, east and south) 
and the diversity of veterinarians participating (more than 20 different vets) in the 
present study, it can be considered that the sample of enrolled horses represents the 
Spanish equine population. 
As previously reported by Todhunter and Lust, (1992) due to the clinical symptoms, in 
the present work many of the horses had to reduce their level of sport activity once 
the symptoms appeared, one of the main non-clinical symptoms associated with this 
disease. 
In this work the diagnosis of the disease was designed according to the gold standard 
in equine practices, and has been previously reported in other clinical trials: Lynn et al., 
2004; Cayzer et al., 2011; Tnibar et al., 2015. 
The lameness grade has been elected as the primary endpoint since is the most 
limiting symptom in equine practices. Likewise as previously explained, the objective of 
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this work was not limited to reduce the degree of lameness, it aimed was to reduce 
the level of lameness to a non-lame or inconsistent lameness that would allow the 
horse to restore its normal work.  Therefore, it has been considered that those horses 
that have reduced their lameness to non-lame or inconsistent lameness could have an 
activity level at least similar to the one before the symptoms appear. 
Treatment with MSCs from the umbilical cord have shown great efficacy in the 
lameness reduction to a non-lame or inconsistent lameness (primary endpoint). This 
lameness reduction is similar to the one obtained with allogenic chondrogenic induced 
peripheral blood MSCs in a recent study developed under Good Clinical Practices in 
Belgium (Broeckx et al.,2019).  
In addition to the measured objective made by the veterinarians using the AAEP 
guidelines, a subjective improvement assessment was made by both the owner and 
the researcher. In this subjective assessment both the owner and the veterinary were 
asked about the improvement in cold immediately outside the box, during the exercise 
practice, the degree of improvement in the sport skills and pain sensation. 
The mean subjective improvement of the horses treated with EUC-MSC was 65% by 
the owner and 64% by the veterinarian compared with 28% (owner) and 29% 
(veterinary) in the placebo group. 
In the work of Broeckx et al., (2019) also the owner was asked about the subjective 
improvement with a 74.8% of overall improvement. This improvement could be 
considered slightly higher than the one observed with EUC-MSCs. However, it is 
important to highlight that in the Broeckx et al, study only one question was made, 
“improvement”. In the present study, 4 different questions were made, therefore, the 
variability in the response is higher and the mean improvement is reduced. 
Interestingly, in the study carried out here, the subjective evaluation of the owner was 
not only made, but also the veterinarian was asked. The high correlation in the results 
observed between veterinarian and owner is particularly interesting. This fact 
highlights the high clinical judgment of equine owners in the improvement assessment 
of their animals. 
Another interesting part of this study is the deep investigation made on the possible 
co-variables involved in the efficacy outcome of EUC-MSCs. 
In the bibliography, it has been reported that different co-variables that could affect 
the effectiveness in OA treatments could exist. Kristiansen et al., (2007) reported that 
the lameness grade negatively affects the response to the treatment. On the other 
hand, Dyson et al., (1991) did not find any relationship between lameness grade and 
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response to treatment. However, the efficacy of EUC-MSC is not affected by the 
equine lameness grade before product administration. 
With respect to the radiographic signs Kristiansen et al., (2007) reported that severe 
radiographic changes negatively affect the prognosis. In the present study the same 
seems to occur; however, this difference was not statistically significant (p= 0.0728) 
According to the age of the animal the correlation between age and responses to 
treatment in osteoarthritis (OA) has not been well established in the bibliography. It 
would be expected that older animals should have worse results although, Kristiansen 
et al., (2007), reported in their study that younger horses had worse treatment 
prognosis than adult horses. On the other hand, de Grauw et al., (2014) showed that 
old horses (more than 13 years old) had a greater incidence of treatment failure when 
treated with triamcinolone + hyaluronic acid. In this study the efficacy was not affected 
with the age of the animal. 
Another point that could have impacted in the effectiveness of the product from a 
theoretical point of view could be the chronicity.  However, a negative correlation 
between chronicity and success of the treatment was not reported in Spadari et al., 
(2014) study, were the efficacy in acute OA was 71.43% vs 95.73% in the chronic OA 
group. On the other hand, Kristiansen et al., (2007) reported that horses with 
chronicity ≤ 3 months showed better results than the ones with more lameness 
chronicity. However in Kristiansen’s study horses suffered from several conditions 
involving tendon and ligament lesions, which could explain the contradictory results 
obtained when compared with Spadari’s work were only OA horses were included. 
In addition, the anatomical location of the injury could also affect the efficacy of the 
product, considering that some joints could have better prognosis than others. 
However, this hypothesis has not been reported previously in the bibliography. Works 
from Spadari et al., (2014); de Grauw et al., (2014) and Broeckx et al., (2013) where 
different joints were enrolled, did not show that the efficacy of the treatment could 
depend on the treated joint. 
According to the bibliography the impact of different co-variables in the efficacy of an 
intra-articular product in OA diagnosed horses is not clear, therefore, in the present 
study, the possible impact of co-variables has been deeply investigated. 
The election of the co-variables was based in veterinary parameters: clinical 
experience of the author and bibliographic research, considering that those variables 
could have some kind of influence in the efficacy of the product. The investigated co-
variables were: lameness grade, radiological degree, age, life habits, affected joint, 
chronicity and activity level. The statistical study performed showed that none of the 
aforementioned co-variables had influence in the efficacy outcome. 
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The efficacy of MSCs in horses with mild to moderate OA can be considered to be an 
efficacy not dependent on environmental or epidemiological factors. Therefore, EUC-
MSC can be considered to have a solid efficacy in horses with OA regardless of their 
age, affected joint, level of sports activity, radiological changes, degree of lameness, 
etc. 
In light of the results, EUC-MSC can be considered a real therapeutic alternative to 
conventional treatments (COs + HA). As it has been seen, the effectiveness of both 
products is comparable, however, the safety profile of the EUC-MSC together with its 
long-time therapeutic action. This provides some medium-term advantages that make 
the EUC-MSC can be an excellent therapeutic alternative to conventional treatments, 
especially in sports or young horses where repeated administration of corticosteroids 
can be widely contraindicated. 
According to safety, the health status of the animals was monitored widely throughout 
the entire study; horses were examined 24h after product administration and at day 
14, 35 and 63 by the veterinarian. In addition, the horse owner (or horse caregiver) 
checked daily the animal and in case signs of illness were observed the veterinary 
should be called immediately.  
During the present study no systemic symptoms related to the administration of EUC-
MSCs were detected. No anomalies were detected in the biochemical or 
haematological values of the horses after the administration of the product. Likewise, 
no adverse events related to the injection point were detected. 
However, there were local orthopaedic adverse events (AE) directly related to the 
administration of the product.  
With ⋍10% incidence, horses treated with EUC-MSCs presented an acute inflammation 
accompanied by local pain and severe lameness, 24 hours after the administration of 
the product. This phenomenon commonly known as joint flare has been previously 
described in the equine practice after use of cellular products or even conventional 
medicines (Ferris et al., 2014). 
This joint flare after the administration of mesenchymal stem cells products have been 
reported after both autologous and allogenic MSCs with similar incidence. In Ferris´s et 
al. work, the incidence of joint flare after autologous bone marrow MSC administration 
in horses was 9%. In addition, the incidence of joint flare reported in the scientific 
information of two very common hyaluronate sodium for horses Hyvisc® and Hylartin-
V® reported and incidence of 12% and 9% respectively (Ferris et al., 2014). This joint 
flare incidence is comparable to the one obtained after EUC-MSCs administration.  
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It is important to point out that, as described Ferris´s publication, despite the adverse 
event, the efficacy of the product was not negatively affected. In the present study, 3 
out of the 4 horse with joint flare of them were classified as therapeutic success (75%); 
so the efficacy of the product was not negatively affected by the appearance of this 
AE. 
In all the joint flare cases registered in the study, horses were treated with NSAIDs for 
pain control and lameness for 3 days. After 24h the horses presented a substantial 
improvement and complete resolution 2 weeks after. 
Another point of special relevance in the use of allogenic cell products is to clarify the 
reason for this inflammatory reaction, which could be confused with an immunological 
reaction to the allogenic use of MSCs by its nature. 
However, despite the fact that the exact cause of the joint flare is not clear, it seems 
clear that an immunological reaction to the allogenic use of MSCs is not the cause. 
Two reasons support it:  
1) the incidence of joint flare in autologous products is similar to allogenic 
products  
2) MSCs lack Mayor Histocompatibility Complex II (MHC-II) so immune response is 
not expected. 
Some authors have postulated that it may be due to a reaction to the Fetal Bovine 
Serum (FBS) used for the cellular expansion in this type of products. In fact, anti-FBS 
antibodies have been found in horses prior to MSC injection, maybe due to vaccines 
preparations; however the titres showed no increase after MSCs application 
(Barrachina et al., 2018). Therefore, the relevance of this is not fully understood. 
Another cause that can contribute to joint flare is that the joint is a closed space with a 
barrier (the synovial membrane) that does not allow the proteins to be balanced 
between systemic circulation and joint causing a greater local inflammation. 
In addition, in the experience of the author, also the exquisite sensibility of the equine 
joints could have an influence in the incidence of joint flare, since in dogs after 
intraarticular administration of autologous, allogenic or even xenogeneic MSCs, the 
incidence of joint flare is much lower than in horses (unpublished data).Therefore, the 
cause of joint flare can be considered to be multifactorial. 
In the author's experience, this incidence can be significantly reduced if prior to the 
administration of EUC-MSC a single dose of NSAIDs is administered to the horse 
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(unpublished data). The use of NSAIDs as preventive of joint flare adverse event in 
advance therapies have been previously use in Broeckx et al., 2019. 
By last, both the efficacy and the safety have been evaluated in a long-term study. 
Although it is true that this part of the study was not carried out under good clinical 
practices and that the veterinarian was not blind and therefore certain bias could 
occur, it is indisputable that the efficacy of the EUC-MSC is long-term. 70% of the 
horses did not relapse in their symptoms or need re-treatment in the following 12 
months after EUC-MSC administration. According to the safety none of the animals 
suffered adverse event suspected of being related to EUC-MSC along the 2-years of the 
follow up. However, the results from this 2 years follow-up study are interesting since 
it is important to highlight that the use of concomitant treatments, change in routine 
habits, and change of activity level was not registered so their impact in the efficacy 
could not be ignored. 
 
 





















8. CONCLUSIONS / CONCLUSIONES 
CONCLUSIONS / CONCLUSIONES 
 
  Page 104 of 114 
8. CONCLUSIONS 
In this work, we can conclude that: 
1. The robust design of the present clinical study, following the European 
directives and regulations related to the design and conduct of clinical trials, 
together with an execution without relevant deviations has allowed  to obtain 
solid and reliable results. The use of EUC-MSC in horses with mild to moderate 
OA has proven effective in reducing lameness in horses under field conditions. 
72% of the horses treated with EUC-MSC presented a reduction in the degree 
of their lameness (non-lameness or inconsistent lameness) 35 days post 
administration onwards. 
 
2. The EUC-MSCs have proven to be safe in their intra-articular use. According to 
the data obtained, the EUC-MSCs are safe in their allogeneic use, presenting no 
serious or systemic adverse effects in any treated animal. However, local 
adverse effects such as joint effusion and lameness have been detected with a 
relatively high incidence (10%) after product injection. These local 
inflammations, commonly known as Joint Flare, are self-limiting, do not 
negatively affect the effectiveness of the cells and do not leave sequel in the 
horse. 
 
3. The present work has shown that the efficacy of the EUC-MSC in reducing 
equine lameness is consistent and is not affected by epidemiological factors 
such as the age of the horse, the affected joint, the chronicity of symptoms, the 
level of activity sports, etc. 
 
4. The EUC-MSC can be considered an innovative alternative treatment to 
conventional treatments since its high efficacy combined with high safety 
profile highlight EUC-MSC as a clear therapeutic alternative for horses with mild 
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CONCLUSIONES 
De este trabajo se pueden extraer las siguientes conclusiones: 
1. El robusto diseño del presente estudio clínico, siguiendo las directivas y 
normativas europeas relativas a diseño y ejecución de ensayos clínicos, unido a 
una ejecución sin desviaciones relevantes al protocolo han permitido obtener 
unos resultados sólidos y confiables. El uso de EUC-MSC en caballos con OA de 
leve a moderada ha demostrado ser eficaz en la reducción de la cojera en 
caballos en condiciones de campo. El 72% de los caballos tratados con EUC-
MSC presentaron una reducción del grado de su cojera a partir de 35 días post 
administración, quedando sin cojera o con una cojera inconsistente. 
 
2. Las EUC-MSC han demostrado ser seguras en su uso intra-articular. Según los 
datos obtenidos, las EUC-MSC son seguras en su uso alogénico, no presentando 
efectos adversos graves ni sistémicos en ningún animal tratado. Sin embargo, 
se han detectado efectos adversos locales como efusión articular y cojera con 
una incidencia relativamente alta (10%) después de la aplicación del producto. 
Estas inflamaciones locales, comúnmente conocidas como Joint Flare, son 
autolimitantes, no afectan negativamente la efectividad de las células y no 
dejan secuelas. 
 
3. El presente trabajo ha demostrado que la eficacia de las EUC-MSC en la 
reducción de la cojera equina es consistente no viéndose afecta por factores 
epidemiológicos como la edad del caballo, la articulación afectada, la 
cronicidad de los síntomas, el nivel de actividad deportiva, etc. 
 
4. Las EUC-MSC pueden ser consideradas un tratamiento innovador alternativo a 
los tratamientos convencionales ya que su alta eficacia unida a su baja tasa de 
efectos adversos posicionan a las EUC-MSC como una clara alterativa 
terapéutica para caballos con OA de leve a moderada.  
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